U.S. patent application number 13/939153 was filed with the patent office on 2013-11-14 for novel biaromatic compounds that modulate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof.
The applicant listed for this patent is Galderma Research & Development. Invention is credited to Corinne Millois BARBUIS, Jean-Guy BOITEAU, Laurence CLARY.
Application Number | 20130303549 13/939153 |
Document ID | / |
Family ID | 34952853 |
Filed Date | 2013-11-14 |
United States Patent
Application |
20130303549 |
Kind Code |
A1 |
BOITEAU; Jean-Guy ; et
al. |
November 14, 2013 |
NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARY TYPE RECEPTORS AND
COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF
Abstract
Novel biaromatic compounds having the general formula (I):
##STR00001## and cosmetic/pharmaceutical compositions comprised
thereof are useful in human or veterinary medicine (in dermatology
and also in the fields of cardiovascular diseases, of immune
diseases and/of diseases related to the metabolism of lipids), or,
alternatively, in cosmetic compositions.
Inventors: |
BOITEAU; Jean-Guy;
(Saint-Aunes, FR) ; CLARY; Laurence; (La Colle Sur
Loup, FR) ; BARBUIS; Corinne Millois; (Saint-Raphael,
FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Galderma Research & Development |
Biot |
|
FR |
|
|
Family ID: |
34952853 |
Appl. No.: |
13/939153 |
Filed: |
July 10, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13353125 |
Jan 18, 2012 |
8513297 |
|
|
13939153 |
|
|
|
|
11802234 |
May 21, 2007 |
8129416 |
|
|
13353125 |
|
|
|
|
PCT/EP2005/013533 |
Nov 17, 2005 |
|
|
|
11802234 |
|
|
|
|
60631989 |
Dec 1, 2004 |
|
|
|
Current U.S.
Class: |
514/256 ;
514/352; 514/357; 514/438; 514/471; 544/335; 546/309; 546/335;
549/496; 549/77 |
Current CPC
Class: |
A61P 37/00 20180101;
A61P 3/04 20180101; A61P 9/12 20180101; C07D 239/26 20130101; C07D
333/24 20130101; C07D 213/75 20130101; A61P 29/00 20180101; A61P
17/00 20180101; C07D 213/55 20130101; C07D 307/54 20130101; A61P
35/00 20180101; A61P 3/10 20180101; C07D 239/42 20130101; A61P 9/00
20180101; A61P 9/10 20180101 |
Class at
Publication: |
514/256 ;
514/352; 514/357; 514/438; 514/471; 544/335; 546/309; 546/335;
549/77; 549/496 |
International
Class: |
C07D 333/24 20060101
C07D333/24; C07D 213/55 20060101 C07D213/55; C07D 307/54 20060101
C07D307/54; C07D 239/26 20060101 C07D239/26 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 19, 2004 |
FR |
0412326 |
Claims
1. A biaromatic compound having the following general formula (I):
##STR00021## in which: R1 is a radical of formula (a) or (b) below:
##STR00022## wherein R5 is as defined below; R2 is a radical of
formula (CH.sub.2).sub.m--NR.sub.6--CQ-(NH).sub.nR.sub.7, wherein
Q, R6, R7, m and n are as defined below; R3 and R4, which may be
identical or different, are each a hydrogen atom, a halogen atom, a
linear or cyclic alkyl radical having from 1 to 12 carbon atoms
that may be interrupted with oxygen, fluorine or nitrogen atoms, a
hydroxyl radical, an alkoxy radical having from 1 to 10 carbon
atoms, a polyether radical, an aralkyl radical or an aryloxy
radical; R5 is a hydroxyl radical, a radical OR8 or a hydroxylamine
radical, wherein R8 is as defined below; R6 is a lower alkyl
radical having from 1 to 4 carbon atoms; R7 is an alkyl radical
having from 1 to 12 carbon atoms, an aryl radical, an aralkyl
radical, a heteroaryl radical or a heterocyclic radical; R8 is an
alkyl, aryl or aralkyl radical; m and n have the values 0 or 1; Q
is an oxygen or sulfur atom; one of Ar1 and Ar2 is a furanyl, and
the other one of Ar1 and Ar2 is phenyl, R9 is a hydrogen atom or an
alkyl radical having from 1 to 12 carbon atoms; or an optical or
geometrical isomer of said compound of formula (I), or a salt
thereof.
2. The biaromatic compound as defined by claim 1, wherein formula
(I), R1 is a radical of formula (a).
3. The biaromatic compound as defined by claim 1, wherein formula
(I), R1 is a radical of formula (b).
4. The biaromatic compound as defined by claim 1, wherein formula
(I), R5 is a hydroxyl radical.
5. The biaromatic compound as defined by claim 1, wherein formula
(I), R5 is a radical OR8.
6. The biaromatic compound as defined by claim 1, wherein formula
(I), R5 is a hydroxylamine radical.
7. The biaromatic compound as defined by claim 1, wherein formula
(I), Q is an oxygen atom.
8. The biaromatic compound as defined by claim 1, wherein formula
(I), Q is a sulfur atom.
9. The biaromatic compound as defined by claim 1, being a salt of
an alkali metal or alkaline-earth metal or a salt of an organic
amine.
10. The biaromatic compound as defined by claim 1, having at least
one halogen atom substituent.
11. The biaromatic compound as defined by claim 1, having at least
one methyl, ethyl, isopropyl, butyl, isobutyl, tert-butyl, hexyl,
heptyl, octyl, decyl, cyclopentyl, cyclohexyl or
methylenecyclopropyl radical substituent.
12. The biaromatic compound as defined by claim 1, having at least
one methyl, ethyl, n-propyl, i-propyl, c-propyl, methylcyclopropyl,
n-butyl, i-butyl or t-butyl radical substituent.
13. The biaromatic compound as defined by claim 1, having at least
one methoxy, ethoxy, isopropyloxy, methylcyclopropyloxy, isobutoxy,
tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy,
benzyloxy, aryloxy or phenoxy radical substituent, which may
optionally be substituted with an alkyl radical having from 1 to 12
carbon atoms or an alkoxy radical having from 1 to 5 carbon
atoms.
14. The biaromatic compound as defined by claim 1, having at least
one methoxymethoxy, ethoxymethoxy or methoxyethoxymethoxy radical
substituent.
15. The biaromatic compound as defined by claim 1, having at least
one benzyl, phenethyl or 2-naphthylmethyl radical substituent,
which may be mono- or disubstituted with a halogen atom, a CF.sub.3
radical, an alkyl radical having from 1 to 12 carbon atoms, an
alkoxy radical having from 1 to 7 carbon atoms, a nitro function, a
polyether radical, an aryl radical, a benzoyl radical, an alkyl
ester group, a carboxylic acid, a hydroxyl radical optionally
protected with an acetyl or benzoyl group or an amino function
optionally protected with an acetyl or benzoyl group or optionally
substituted with at least one alkyl radical having from 1 to 12
carbon atoms.
16. The biaromatic compound as defined by claim 1, having at least
one phenyl, biphenyl, cinnamyl or naphthyl radical substituent,
which may be mono- or disubstituted with a halogen atom, a CF.sub.3
radical, an alkyl radical having from 1 to 12 carbon atoms, an
alkoxy radical having from 1 to 7 carbon atoms, a nitro function, a
polyether radical, an aryl radical, a benzoyl radical, an alkyl
ester group, a carboxylic acid, a hydroxyl radical optionally
protected with an acetyl or benzoyl group or an amino function
optionally protected with an acetyl or benzoyl group or optionally
substituted with at least one alkyl radical having from 1 to 12
carbon atoms.
17. The biaromatic compound as defined by claim 1, having at least
one furyl, thienyl, isoxazolyl, oxadiazolyl, oxazolyl,
isothiazolyl, quinazolinyl, benzothiadiazolyl, benzimidazolyl,
quinoxalyl, indolyl or benzofuryl radical substituent, optionally
substituted with at least one halogen atom, an alkyl radical having
from 1 to 12 carbon atoms, an alkoxy having from 1 to 7 carbon
atoms, an aryl radical, a nitro function, a polyether radical, a
heteroaryl radical, a benzoyl radical, an alkyl ester group, a
carboxylic acid, a hydroxyl radical optionally protected with an
acetyl or benzoyl group or an amino function optionally protected
with an acetyl or benzoyl group or optionally substituted with at
least one alkyl radical having from 1 to 12 carbon atoms.
18. The biaromatic compound as defined by claim 1, having at least
one morpholino, piperidino, piperazino, 2-oxo-1-piperidyl or
2-oxo-1-pyrrolidinyl radical substituent, optionally substituted
with at least one alkyl radical having from 1 to 12 carbon atoms,
an alkoxy radical having from 1 to 7 carbon atoms, an aryl radical,
a nitro function, a polyether radical, a heteroaryl radical, a
benzoyl radical, an alkyl ester group, a carboxylic acid, a
hydroxyl radical optionally protected with an acetyl or benzoyl
group or an amino function optionally protected with an acetyl or
benzoyl group or optionally substituted with at least one alkyl
radical having from 1 to 12 carbon atoms.
19. The biaromatic compound as defined by claim 1, selected from
the group consisting of:
3-(5-{3-[(Methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylic
acid,
3-[5-[3-(3-Heptyl-1-methylureido)phenyl]-4-(2,2,2-trifluoroethoxy)furan-2-
-yl]propanoic acid,
3-(5-{3-[3-(3,5-Dimethoxyphenyl)-1-ethylureido]phenyl}-3-methylfuran-2-yl-
)propanoic acid,
3-{5-[3-(3-Heptyl-1-methylureido)-4-trifluoromethylphenyl]furan-2-yl}prop-
anoic acid, and mixtures thereof.
20. The biaromatic compound as defined by claim 1, wherein formula
(I) at least one of the following conditions is satisfied: R3 is an
alkoxy radical having from 1 to 7 carbon atoms; R5 is a hydroxyl
radical; in the sequence
--(CH.sub.2).sub.m--NR.sub.6--CQ(NH).sub.nR.sub.7, m=0, n=1; Q is
an oxygen atom; R7 is an alkyl radical having from 1 to 8 carbon
atoms.
21. The biaromatic compound as defined by claim 1, wherein formula
(I) all of the following conditions are satisfied: R3 is an alkoxy
radical having from 1 to 7 carbon atoms; R5 is a hydroxyl radical;
in the sequence --(CH.sub.2).sub.m--NR.sub.6--CQ(NH).sub.nR.sub.7,
m=0, n=1; Q is an oxygen atom; R7 is an alkyl radical having from 1
to 8 carbon atoms.
22. A cosmetic composition comprising a cosmetically effective
amount of at least one biaromatic compound as defined by claim 1,
formulated into a cosmetically and physiologically acceptable
support therefor.
23. The cosmetic composition as defined by claim 22, comprising
from 0.0001% to 2% by weight of said at least one biaromatic
compound.
24. The cosmetic composition as defined by claim 20, formulated for
body or hair hygiene.
25. A pharmaceutical composition comprising a pharmaceutically
effective amount of at least one biaromatic compound as defined by
claim 1, formulated into a pharmaceutically and physiologically
acceptable support therefor.
26. The pharmaceutical composition as defined by claim 25,
comprising from 0.001% to 10% by weight of said at least one
biaromatic compound.
27. A method for activating PPAR.gamma. receptors, said method
comprising contacting said receptors with an effective PPAR.gamma.
receptor activating amount of a biaromatic compound as defined by
claim 1.
Description
CROSS-REFERENCE TO EARLIER APPLICATIONS
[0001] This application is a divisional of copending U.S.
application Ser. No. 13/353,125, filed Jan. 18, 2012, now allowed,
which is a divisional of U.S. application Ser. No. 11/802,234,
filed May 21, 2007, now U.S. Pat. No. 8,129,416, which is a
continuation of PCT/EP2005/013533 filed Nov. 17, 2005 and
designating the United States, published in the English language as
WO 2006/053791 A3 on May 26, 2006, which claims benefit of U.S.
Provisional Application No. 60/631,989, filed Dec. 1, 2004 and also
claims priority of FR 04/12326, filed Nov. 19, 2004, each hereby
expressly incorporated by reference in its entirety and each
assigned to the assignee hereof.
BACKGROUND OF THE INVENTION
[0002] 1. Technical Field of the Invention
[0003] The present invention relates to, as novel and useful
industrial products, a novel class of compounds that are modulators
of receptors of Peroxisome Proliferator-Activated Receptor type of
subtype .gamma. (PPAR.gamma.). This invention also relates to a
process for the preparation of same and to their formulation into
pharmaceutical compositions useful in human or veterinary medicine,
or, alternatively, into cosmetic compositions.
[0004] 2. Description of Background and/or Related and/or Prior
Art
[0005] The activity of receptors of PPAR type has been the subject
of many studies. See, for example, the publication entitled
"Differential Expression of Peroxisome Proliferator-Activated
Receptor Subtypes During the Differentiation of Human
Keratinocytes", Michel Rivier et al., J. Invest. Dermatol., 111,
1998, pp. 1116-1121, in which is listed a large number of
bibliographic references relating to receptors of PPAR type. See
also the report entitled "The PPARs: From orphan receptors to Drug
Discovery", Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach
and Brad R. Henke, J. Med. Chem., 2000, Vol. 43, pp. 527-550.
[0006] PPAR receptors activate transcription by binding to elements
of DNA sequences, known as peroxisome proliferator response
elements (PPRE), in the form of a heterodimer with retinoid X
receptors (known as RXRs).
[0007] Three subtypes of human PPARs have been identified and
described: PPAR.alpha., PPAR.gamma. and PPAR.delta. (or NUC1).
[0008] PPAR.alpha. is mainly expressed in the liver, while
PPAR.delta. is ubiquitous.
[0009] PPAR.gamma. is the most extensively studied of the three
subtypes. All the references suggest a critical role of PPAR.gamma.
in regulating the differentiation of adipocytes, where it is
greatly expressed. It also plays a key role in systemic lipid
homeostasis.
[0010] It has been described, in particular, in WO 96/33724 that
PPAR.gamma.-selective compounds, such as a prostaglandin-J2 or -D2,
are potential active agents for treating obesity and diabetes.
[0011] Moreover, the assignee hereof has already described
PPAR.gamma. compounds and/or the use thereof in FR-2,773,075, which
describes the use of PPAR.gamma. activator compounds in the
preparation of a pharmaceutical composition, the composition being
useful to treat skin disorders associated with an anomaly of
epidermal cell differentiation.
SUMMARY OF THE INVENTION
[0012] The present invention features a novel class of
PPAR.gamma.-modulating compounds that show very good specific
affinity for PPAR.gamma..
[0013] Thus, the present invention features novel biaromatic
compounds having the general formula (I) below:
##STR00002##
in which:
[0014] R1 is a radical of formula (a) or (b) below:
##STR00003##
wherein R5 is as defined below;
[0015] R2 is a radical of formula
(CH.sub.2).sub.m--NR.sub.6--CQ-(NH).sub.nR.sub.7, wherein Q, R6,
R7, m and n are as defined below;
[0016] R3 and R4, which may be identical or different, are each a
hydrogen atom, a halogen atom, a linear or cyclic alkyl radical
having from 1 to 12 carbon atoms that may be interrupted with
oxygen, fluorine or nitrogen atoms, a hydroxyl radical, an alkoxy
radical having from 1 to 10 carbon atoms, a polyether radical, an
aralkyl radical or an aryloxy radical;
[0017] R5 is a hydroxyl radical, a radical OR8 or a hydroxylamine
radical, wherein R8 is as defined below;
[0018] R6 is a lower alkyl radical having from 1 to 4 carbon
atoms;
[0019] R7 is an alkyl radical having from 1 to 12 carbon atoms, an
aryl radical, an aralkyl radical, a heteroaryl radical or a
heterocyclic radical;
[0020] R8 is an alkyl, aryl or aralkyl radical;
[0021] m and n have the values 0 or 1;
[0022] Q is an oxygen or sulfur atom;
[0023] Ar1 and Ar2, which may be identical or different, are each
an optionally substituted aromatic radical of one of the
formulae:
##STR00004##
[0024] A is a sulfur or oxygen atom or a radical N--R9;
[0025] R9 is a hydrogen atom or an alkyl radical having from 1 to
12 carbon atoms;
with the proviso that when Ar1 or Ar2 is an aryl radical, then Ar2
or Ar1 is necessarily a heteroaryl radical, and the optical and
geometrical isomers of said compounds of formula (I), and also the
salts thereof.
[0026] In particular, when the compounds according to the invention
are in the form of salts, they are salts of an alkali metal, in
particular a sodium or potassium salt, or salts of an
alkaline-earth metal or salts of organic amines, more particularly
of amino acids such as arginine or lysine. In the case of compounds
containing nitrogen heterocycles, the salts may be of mineral or
organic acids.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIGS. 1-4 show a variety of reaction schemes for the
ultimate preparation of the biaromatic compounds according to the
present invention.
DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED
EMBODIMENTS OF THE INVENTION
[0028] According to the present invention, the term "hydroxyl
radical" means an --OH radical.
[0029] The term "halogen atom" means a fluorine, chlorine or
bromine atom.
[0030] According to the present invention, the term "alkyl radical
having from 1 to 12 carbon atoms" means a saturated or unsaturated,
linear or cyclic, optionally branched, hydrogenated or fluorinated
radical having from 1 to 12 carbon atoms, which may be interrupted
with a hetero atom, and the alkyl radicals having from 1 to 12
carbon atoms are preferably methyl, ethyl, isopropyl, butyl,
isobutyl, tert-butyl, hexyl, heptyl, octyl, decyl, cyclopentyl,
cyclohexyl or methylenecyclopropyl radicals.
[0031] The alkyl radicals having from 1 to 4 carbon atoms will
preferably be methyl, ethyl, n-propyl, i-propyl, c-propyl,
methylcyclopropyl, n-butyl, i-butyl or t-butyl radicals.
[0032] The term "alkoxy radical having from 1 to 7 carbon atoms"
means a methoxy, ethoxy, isopropyloxy, methylcyclopropyloxy,
isobutoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy,
heptyloxy, benzyloxy, aryloxy or phenoxy radical, which may be
optionally substituted with an alkyl radical having from 1 to 12
carbon atoms or an alkoxy radical having from 1 to 5 carbon
atoms.
[0033] The term "polyether radical" means a polyether radical
having from 1 to 6 carbon atoms interrupted with at least one
oxygen atom, such as methoxymethoxy, ethoxymethoxy or
methoxyethoxymethoxy radicals.
[0034] The term "aralkyl radical" means a benzyl, phenethyl or
2-naphthylmethyl radical, which may be mono- or disubstituted with
a halogen atom, a CF.sub.3 radical, an alkyl radical having from 1
to 12 carbon atoms, an alkoxy radical having from 1 to 7 carbon
atoms, a nitro function, a polyether radical, an aryl radical, a
benzoyl radical, an alkyl ester group, a carboxylic acid, a
hydroxyl radical optionally protected with an acetyl or benzoyl
group or an amino function optionally protected with an acetyl or
benzoyl group or optionally substituted with at least one alkyl
having from 1 to 12 carbon atoms.
[0035] The term "aryl radical" means a phenyl, biphenyl, cinnamyl
or naphthyl radical, which may be mono- or disubstituted with a
halogen atom, a CF.sub.3 radical, an alkyl radical having from 1 to
12 carbon atoms, an alkoxy radical having from 1 to 7 carbon atoms,
a nitro function, a polyether radical, an aryl radical, a benzoyl
radical, an alkyl ester group, a carboxylic acid, a hydroxyl
radical optionally protected with an acetyl or benzoyl group or an
amino function optionally protected with an acetyl or benzoyl group
or optionally substituted with at least one alkyl having from 1 to
12 carbon atoms.
[0036] The term "heteroaryl radical" means an aryl radical
interrupted with one or more hetero atoms, such as a pyridyl,
furyl, thienyl, isoxazolyl, oxadiazolyl, oxazolyl, isothiazolyl,
quinazolinyl, benzothiadiazolyl, benzimidazolyl, quinoxalyl,
indolyl or benzofuryl radical, optionally substituted with at least
one halogen, an alkyl radical having from 1 to 12 carbon atoms, an
alkoxy radical having from 1 to 7 carbon atoms, an aryl radical, a
nitro function, a polyether radical, a heteroaryl radical, a
benzoyl radical, an alkyl ester group, a carboxylic acid, a
hydroxyl group optionally protected with an acetyl or benzoyl group
or an amino function optionally protected with an acetyl or benzoyl
group or optionally substituted with at least one alkyl radical
having from 1 to 12 carbon atoms.
[0037] The term "heterocyclic radical" preferably means a
morpholino, piperidino, piperazino, 2-oxo-1-piperidyl or
2-oxo-1-pyrrolidinyl radical, optionally substituted with at least
one alkyl radical having from 1 to 12 carbon atoms, an alkoxy
radical having from 1 to 7 carbon atoms, an aryl radical, a nitro
function, a polyether radical, a heteroaryl radical, a benzoyl
radical, an alkyl ester group, a carboxylic acid, a hydroxyl group
optionally protected with an acetyl or benzoyl group or an amino
function optionally protected with an acetyl or benzoyl group or
optionally substituted with at least one alkyl having from 1 to 12
carbon atoms.
[0038] Exemplary compounds of formula (I) according to the present
invention, whether alone or as a mixture, include: [0039] 1.
3-(5-{3-[(Methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylic
acid, [0040] 2.
3-(5-{3-[(Methyloctanoylamino)methyl]phenyl}thiophen-2-yl)propa-
noic acid, [0041] 3.
3-(5-{3-[(Methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylic
acid, [0042] 4.
3-(4-{5-[(Methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acryl- ic
acid, [0043] 5.
3-(4-{5-[(Methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoic
acid, [0044] 6.
3-{4-[6-(3-Heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic acid,
[0045] 7.
3-{6-[3-(3-Heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoic acid,
[0046] 8.
2-[4-(2-Carboxyethyl)phenyl]-4-(3-heptyl-1-methylureido)pyridinium
acetate, [0047] 9.
3-{5-[3-(3-Pentyl-1-methylureido)phenyl]pyrimidin-2-yl}acrylic
acid, [0048] 10.
3-{5-[3-(3-Pentyl-1-methylureido)phenyl]pyrimidin-2-yl}propanoic
acid, [0049] 11.
2-[2-Butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-pentylureido)pyridini-
um hydrochloride, [0050] 12.
2-[2-Butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-heptylureido)pyridini-
um hydrochloride, [0051] 13.
2-[4-(2-Carboxyethyl)-2-ethoxyphenyl]-6-(3-heptyl-1-methylureido)pyridini-
um hydrochloride, [0052] 14.
3-(3-Butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propan-
oic acid, [0053] 15.
3-(3-Butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid, [0054] 16.
3-(3-Butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid, [0055] 17.
3-{5-[4-(3-Heptyl-1-methylureido)pyrid-2-yl]furan-2-yl}propanoic
acid, [0056] 18.
3-[5-[3-(3-Heptyl-1-methylureido)phenyl]-4-(2,2,2-trifluoroethoxy)furan-2-
-yl]propanoic acid, [0057] 19.
3-(5-{3-[3-(3,5-Dimethoxyphenyl)-1-ethylureido]phenyl}-3-methylfuran-2-yl-
)propanoic acid, [0058] 20.
3-(5-{6-[3-(4-Ethoxyphenyl)-1-ethylureido]pyrid-2-yl}furan-2-yl)propanoic
acid, [0059] 21.
3-(2-Methyl-4-{6-[1-methyl-3-(4-methylpentyl)ureido]pyrid-2-yl}phenyl)pro-
panoic acid, [0060] 22. Methyl
3-{4-[6-(1-ethyl-3-naphthalen-2-ylureido)pyrid-2-yl]-2-fluorophenyl}propa-
noate, [0061] 23.
3-(4-{6-[3-(4-Butoxyphenyl)-1-methylureido]pyrid-2-yl}phenyl)-N-hydroxypr-
opionamide, [0062] 24.
3-{3-Cyclopropylmethoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}p-
ropanoic acid, [0063] 25.
3-{4-[6-(1-Ethyl-3-phenylthioureido)pyrid-2-yl]-3-propoxyphenyl}propanoic
acid, [0064] 26.
3-{3-Ethoxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid, [0065] 27.
3-{4-[6-(3-Hexyl-1-methylureido)pyrid-2-yl]-3-isopropoxyphenyl}propanoic
acid, [0066] 28.
3-[4-[6-(3-Heptyl-1-methylureido)pyrid-2-yl]-3-(4,4,4-trifluorobutoxy)phe-
nyl]propanoic acid, [0067] 29.
3-{3-(2-Dimethylaminoethoxy)-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phe-
nyl}propanoic acid, [0068] 30.
3-{3-(3-Hydroxypropoxy)-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}p-
ropanoic acid, [0069] 31.
3-{4-[6-(1-Ethyl-3-phenylthioureido)pyrid-2-yl]-3-fluorophenyl}acrylic
acid, [0070] 32.
3-{4-[6-(3-Hexyl-1-methylureido)pyrid-2-yl]-3-trifluoromethylphenyl}propa-
noic acid, [0071] 33.
3-[6'-(1-Methyl-3-phenethylureido)[2,2']bipyridinyl-5-yl]propanoic
acid, [0072] 34.
3-{2-[6-(3-Hexyl-1-methylureido)pyrid-2-yl]thiazol-4-yl}propanoic
acid, [0073] 35. Ethyl
3-{2-[6-(3-hexyl-1-methylureido)pyrid-2-yl]thiazol-5-yl}propanoate,
[0074] 36.
3-(3-{6-[1-Methyl-3-(6-methylheptyl)ureido]pyrid-2-yl}isoxazol-5-yl)propa-
noic acid, [0075] 37.
3-{4-[2-(3-Heptyl-1-methylureido)pyrimidin-4-yl]phenyl}propanoic
acid, [0076] 38.
3-{3-Cyclopropylmethoxy-4-[2-(3-heptyl-1-methylureido)pyrimidin-4-yl]phen-
yl}propanoic acid, [0077] 39.
3-(4-{2-[1-Ethyl-3-(4-propoxyphenyl)ureido]pyrimidin-4-yl}-3-fluorophenyl-
)propanoic acid, [0078] 40.
3-{2-Fluoro-4-[2-(1-methyl-3-naphthalen-2-ylureido)pyrid-4-yl]phenyl}-N-h-
ydroxypropionamide, [0079] 41.
3-[2'-(3-Hexyl-1-methylthioureido)[2,4']bipyridinyl-5-yl]propanoic
acid, [0080] 42.
3-{4-[2-(3-Hexyl-1-methylureido)pyrid-4-yl]-3-propoxyphenyl}propanoic
acid, [0081] 43.
3-(3-Benzyloxy-4-{4-[1-methyl-3-(5-methylhexyl)ureido]pyrid-2-yl}phenyl)p-
ropanoic acid, [0082] 44.
3-{2-[4-(3-Hexyl-1-methylureido)pyrid-2-yl]thiazol-5-yl}acrylic
acid, [0083] 45.
3-{5-[3-(3-Hexyl-1-methylureido)phenyl]pyrid-2-yl}acrylic acid,
[0084] 46.
3-{5-[5-(3-Heptyl-1-methylthioureido)thiophen-3-yl]pyrid-2-yl}acrylic
acid, [0085] 47.
3-{4-[2-(3-Heptyl-1-methylureido)thiazol-4-yl]-3-propoxyphenyl}propanoic
acid, [0086] 48.
3-(2-Fluoro-4-{5-[(heptanoylmethylamino)methyl]thiophen-3-yl}phenyl)propa-
noic acid, [0087] 49.
3-(4-{5-[(Heptanoylmethylamino)methyl]thiophen-3-yl}-3-isobutoxyphenyl)ac-
rylic acid, [0088] 50.
3-(3-(2-Cyclopentylethoxy)-4-{5-[(methyloctanoylamino)methyl]thiophen-3-y-
l}phenyl)propanoic acid, [0089] 51. Methyl
3-(3-isobutoxy-4-{5-[(methylnonanoylamino)methyl]thiophen-3-yl}phenyl)pro-
panoate, [0090] 52.
3-{6-[5-({Ethyl-[2-(2-pentylphenyl)acetyl]amino}methyl)thiophen-3-yl]pyri-
d-3-yl}propanoic acid, [0091] 53.
3-(4-{4-[(Methylnonanoylamino)methyl]thiazol-2-yl}-3-propoxyphenyl)propan-
oic acid, [0092] 54.
3-(2-Chloro-4-{4-[(methylnonanoylamino)methyl]thiophen-2-yl}phenyl)propan-
oic acid, [0093] 55.
3-(2-Fluoro-4-{4-[(methylnonanoylamino)methyl]thiophen-2-yl}phenyl)acryli-
c acid, [0094] 56.
3-(4-{4-[(Heptanoylmethylamino)methyl]thiophen-2-yl}-1-methyl-1H-pyrrol-2-
-yl)propanoic acid, [0095] 57.
3-(4-{4-[(Heptanoylmethylamino)methyl]thiophen-2-yl}furan-2-yl)propanoic
acid, [0096] 58.
3-{5'-[(Heptanoylmethylamino)methyl][3,3']bithiophenyl-5-yl}propanoic
acid, [0097] 59. Phenyl
3-{5'-[(heptanoylmethylamino)methyl]-3-propyl[2,3']bithiophenyl-5-yl}prop-
anoate, [0098] 60.
3-(5-{5-[(Heptanoylmethylamino)methyl]thiophen-3-yl}-4-propylfuran-2-yl)a-
crylic acid, [0099] 61.
3-{3-Butoxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid, [0100] 62.
3-{3-Benzyloxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid, [0101] 63.
3-{3-Benzyloxy-4-[2-(3-heptyl-1-methylureido)pyrimidin-4-yl]phenyl}propan-
oic acid, [0102] 64.
3-{3-Butyloxy-4-[2-(3-heptyl-1-methylureido)pyrimidin-4-yl]phenyl}propano-
ic acid, [0103] 65.
3-{3-Butoxy-4-[4-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid, [0104] 66.
3-{3-Benzyloxy-4-[4-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid, [0105] 67.
3-{3-Benzyloxy-4-[5-(3-heptyl-1-methylureido)pyrid-3-yl]phenyl}propanoic
acid, [0106] 68.
3-{3-Butoxy-4-[5-(3-heptyl-1-methylureido)pyrid-3-yl]phenyl}propanoic
acid, [0107] 69.
3-(5-{3-[(Methyloctanoylamino)methyl]phenyl}-4-propylthiophen-2-yl)propan-
oic acid, [0108] 70.
3-(3-Benzyloxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl}pro-
panoic acid, [0109] 71.
3-(4-Benzyl-5-{3-[(hexanoylmethylamino)methyl]phenyl}thiophen-2-yl)propan-
oic acid, [0110] 72.
3-{4-Cyclopropylmethyl-5-[3-(1-methyl-3-pentylureido)phenyl]thiophen-2-yl-
}propanoic acid, [0111] 73.
3-{5-[3-(1-Methyl-3-pentylureido)-4-trifluoromethylphenyl]thiophen-2-yl}p-
ropanoic acid, [0112] 74.
3-(5-{3-[3-(4-Butoxyphenyl)-1-ethylureido]phenyl}thiophen-2-yl)propanoic
acid, [0113] 75.
3-{5-[3-(3-Heptyl-1-methylureido)-4-trifluoromethylphenyl]furan-2-yl}prop-
anoic acid, [0114] 76.
3-{2-Butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}propanoic
acid, [0115] 77.
3-{2-(4-Methoxybenzyloxy)-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl-
}propanoic acid, [0116] 78.
3-{2-(3-Methoxybenzyloxy)-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl-
}propanoic acid, [0117] 79.
3-[2-Cyclopropylmethoxy-4-(6-{3-[2-(4-methoxyphenyl)ethyl]-1-methylureido-
}pyrid-2-yl)phenyl]propanoic acid
[0118] According to the present invention, the compounds of formula
(I) that are more particularly preferred are those which satisfy at
least one of the following characteristics: [0119] R3 is an alkoxy
radical having from 1 to 7 carbon atoms; [0120] R5 is to a hydroxyl
radical; the sequence
--(CH.sub.2).sub.m--NR.sub.6--CQ(NH).sub.nR.sub.7 wherein m=0, n=1;
[0121] Q is an oxygen atom; [0122] R7 is an alkyl radical having
from 1 to 8 carbon atoms; at least Ar1 or Ar2 is a group of
pyridine type.
[0123] The present invention also features processes for preparing
the compounds of formula (I), in particular according to the
reaction schemes shown in FIGS. 1, 2, 3 and 4.
[0124] FIG. 1: The boronic acid or ester 2 may be obtained from
compound 1 under standard conditions, for example by reaction with
tert-butyllithium followed by an addition to the trimethyl borate
or reaction with pinacoldiborane in the presence of a palladium
catalyst, for instance diphenylphosphinoferrocenepalladium
dichloride. Compound 1 may also be directly coupled with an
isocyanate, a thioisocyanate or an acyl chloride (in this case n=0)
under standard conditions to give compound 3.
[0125] The boronic acid or ester 4 may be obtained from compound 3
under standard conditions, for example by reaction with
tert-butyllithium followed by an addition to trimethyl borate or
reaction with pinacoldiborane in the presence of a palladium
catalyst, for instance diphenylphosphinoferrocenepalladium
dichloride.
[0126] The compounds 5 may either be purchased commercially or may
be synthesized from the corresponding aldehyde thereof via a Wittig
reaction.
[0127] A Suzuki type palladium coupling from the boronate 4 or 2
and compound 5 (selected from an aryl bromide, iodide, chloride or
triflate) allows the compounds having the aryl-aryl sequence 7 or
9, respectively, to be obtained.
[0128] A Suzuki type palladium coupling from the boronate 4 or 2
and compound 6 (selected from an aryl bromide, iodide, chloride or
triflate) allows the compounds having the aryl-aryl sequence 8 or
11, respectively, to be obtained.
[0129] Compounds 10 and 12 may be obtained from compounds 9 and 11
by deprotection under standard conditions, for example by treatment
with a strong acid, for instance trifluoroacetic acid if P is a Boc
group.
[0130] Compounds 10 and 12 may be coupled with isocyanates,
thioisocyanates or acyl chlorides (in this case n=0) under the
standard conditions to give the compounds 7 and 8 respectively.
[0131] Compounds 8 and 11 may be obtained via hydrogenation of
compounds 7 and 9 under standard hydrogenation conditions, for
instance: hydrogen catalyzed with palladium-on-charcoal.
[0132] The acid functions of compounds 13 and 14 may be obtained
from compounds 7 and 8 respectively: via saponification if R8 is an
alkyl chain, using a base, for instance sodium hydroxide.
[0133] Compound 14 may be obtained via hydrogenation of compound 13
under standard hydrogenation conditions, for instance: hydrogen
catalyzed with palladium-on-charcoal.
[0134] Compounds 15 and 16 may be obtained from the esters 7 and 8,
respectively, via treatment with hydroxylamine.
[0135] FIG. 2: A Suzuki type palladium coupling between a
commercial arylboronic acid containing a formyl group and compounds
1 or 3 (selected from an aryl bromide, iodide, chloride or
triflate) allows the compounds having the aryl-aryl sequence 18 or
17, respectively, to be obtained.
[0136] Compound 18 may be coupled with isocyanates, thioisocyanates
or acyl chlorides (in this case n=1) under standard conditions to
give compound 17.
[0137] Compounds 7 and 9 may be obtained via a Wittig reaction
starting with compounds 17 and 18, respectively, for example via
the action of methyl triphenylphosphoranylideneacetate.
[0138] FIG. 3: A Suzuki type palladium coupling between the boronic
acids or esters 4 or 2 and aryl dihalides selected from bromides,
iodides and chlorides allows the compounds having the aryl-aryl
sequence 19 or 20, respectively, to be obtained.
[0139] Compounds 7 and 9 may be obtained from compounds 19 and 20,
respectively, via a Heck type palladium coupling with alkyl or aryl
acrylates.
[0140] FIG. 4: The boronates 21 and 22 may be obtained by treating
compounds 5 and 6, respectively, with pinacoldiborane, in the
presence of a palladium-based catalyst, for instance
diphenylphosphinoferrocenepalladium dichloride.
[0141] A Suzuki type palladium coupling between compound 21 and
compounds 3 and 1 (selected from an aryl bromide, iodide, chloride
or triflate) allows the compounds having the aryl-aryl sequence 7
and 9, respectively, to be obtained.
[0142] A Suzuki palladium coupling between compound 22 and
compounds 3 and 1 (selected from aryl bromide, iodide, chloride or
triflate) allows compounds having the aryl-aryl sequence 8 and 11,
respectively, to be obtained.
[0143] The compounds according to the invention show modulatory
properties on receptors of PPAR type. This activity on the
PPAR.alpha., .delta. and .gamma. receptors is measured in a
transactivation test and quantified via the dissociation constant
Kdapp (apparent), as described in Example 6.
[0144] The preferred compounds of the present invention have a
dissociation constant of less than or equal to 5,000 nM and
advantageously less than or equal to 1,000 nM.
[0145] Preferably, the compounds are modulators of receptors of
specific PPAR.gamma. type, i.e., they have a ratio between the
Kdapp for the PPAR.alpha. and PPAR.gamma. receptors, and the Kdapp
for the PPAR.gamma. receptors, of greater than or equal to 10.
Preferably, this ratio PPAR.gamma./PPAR.alpha. or
PPAR.gamma./PPAR.gamma. is greater than or equal to 50 and more
advantageously greater than or equal to 100.
[0146] The present invention also features administration of the
compounds of formula (I) as medicaments.
[0147] The present invention also features formulation of the
compounds of formula (I) into compositions for regulating and/or
restoring skin lipid metabolism.
[0148] The compounds according to the invention are also
particularly useful in the following fields of treatments, whether
regime or regimen:
[0149] 1) for treating dermatological complaints, conditions or
afflictions associated with a keratinization disorder relating to
differentiation and to proliferation, in particular for treating
common acne, comedones, polymorphs, rosacea, nodulocystic acne,
acne conglobata, senile acne and secondary acne such as solar,
medicinal or occupational acne,
[0150] 2) for treating other types of keratinization disorders, in
particular ichthyosis, ichthyosiform conditions, Darier's disease,
palmoplantar keratoderma, leukoplakia and leukoplakiform
conditions, and cutaneous or mucous (oral) lichen,
[0151] 3) for treating other dermatological complaints, conditions
or afflictions with an inflammatory immuno-allergic component, with
or without a cellular proliferation disorder, and in particular all
forms of psoriasis, whether cutaneous, mucous or ungual psoriasis,
and even psoriatic arthritis, or alternatively cutaneous atopy such
as eczema, or respiratory atopy or gingival hypertrophy,
[0152] 4) for treating all dermal or epidermal proliferations,
whether benign or malignant, whether or not of viral origin, such
as common warts, flat warts and epidermodysplasia verruciformis,
oral or florid papillomatoses, T lymphoma and proliferations which
may be induced by ultraviolet light, in particular in the case of
basal cell and spinocellular epithelioma, and also any precancerous
skin lesion such as keratoacanthomas,
[0153] 5) for treating other dermatological disorders, conditions
or afflictions such as immune dermatitides, such as lupus
erythematosus, bullous immune diseases and collagen diseases, such
as scleroderma,
[0154] 6) in the treatment of dermatological or systemic conditions
having an immunological component,
[0155] 7) in the treatment of skin disorders due to exposure to UV
radiation, and also for repairing or combating aging of the skin,
whether light-induced or chronological aging, or for reducing
actinic keratoses and pigmentations, or any pathology associated
with chronological or actinic aging, such as xerosis,
[0156] 8) for combating sebaceous function disorders such as the
hyperseborrhoea of acne, simple seborrhoea or seborrhoeic
dermatitis,
[0157] 9) for preventing or treating cicatrization disorders or for
preventing or repairing stretch marks,
[0158] 10) in the treatment of pigmentation disorders, such as
hyperpigmentation, melasma, hypopigmentation or vitiligo,
[0159] 11) in the treatment of lipid metabolism complaints,
conditions or afflictions such as obesity, hyperlipidaemia,
non-insulin-dependent diabetes or syndrome X,
[0160] 12) in the treatment of inflammatory complaints, conditions
or afflictions such as arthritis,
[0161] 13) in the treatment or prevention of cancerous or
precancerous conditions,
[0162] 14) in the prevention or treatment of alopecia of various
origins, in particular alopecia caused by chemotherapy or
radiation,
[0163] 15) in the treatment of immune system disorders, such as
asthma, type I sugar diabetes, multiple sclerosis or other
selective dysfunctions of the immune system, or
[0164] 16) in the treatment of complaints, conditions or
afflictions of the cardiovascular system, such as arteriosclerosis
or hypertension.
[0165] The present invention also features pharmaceutical/cosmetic
compositions comprising, formulated into a physiologically
acceptable medium, at least one compound of formula (I) as defined
above.
[0166] The compositions of this invention may be administered
enterally, parenterally, topically or ocularly. The pharmaceutical
composition is preferably packaged in a form that is suitable for
topical application.
[0167] Via the enteral route, the composition, more particularly
the pharmaceutical composition, may be in the form of tablets, gel
capsules, sugar-coated tablets, syrups, suspensions, solutions,
powders, granules, emulsions or lipid or polymer vesicles or
nanospheres or microspheres to allow controlled release. Via the
parenteral route, the composition may be in the form of solutions
or suspensions for infusion or for injection.
[0168] The compounds according to the invention are generally
administered at a daily dose of about 0.001 mg/kg to 100 mg/kg of
body weight in 1 to 3 dosage intakes.
[0169] The compounds are administered systemically at a
concentration generally of from 0.001% to 10% by weight and
preferably from 0.01% to 1% by weight relative to the weight of the
composition.
[0170] Via the topical route, the pharmaceutical composition
according to the invention is more particularly intended for
treating the skin and mucous membranes and may be in the form of
ointments, creams, milks, salves, powders, impregnated pads,
syndets, solutions, gels, sprays, foams, suspensions, stick
lotions, shampoos or washing bases. It may also be in the form of
suspensions of lipid or polymer vesicles or nanospheres or
microspheres or polymer patches and hydrogels to allow controlled
release. This topical-route composition may be in anhydrous form,
in aqueous form or in the form of an emulsion.
[0171] The compounds are administered topically at a concentration
generally of from 0.001% to 10% by weight, preferably from 0.01% to
1% by weight relative to the total weight of the composition.
[0172] The compounds of formula (I) according to the invention also
find an application in the cosmetic field, in particular in body
and hair hygiene and more particularly for regulating and/or
restoring skin lipid metabolism.
[0173] This invention therefore also features the cosmetic
application of a composition comprising, in a physiologically
acceptable support, at least one of the compounds of formula (I)
for body or hair hygiene.
[0174] The cosmetic compositions according to the invention
containing, in a cosmetically acceptable support, at least one
compound of formula (I) or an optical or geometrical isomer thereof
or a salt thereof, may usually be in the form of a cream, a milk, a
lotion, a gel, suspensions of lipid or polymer vesicles or
nanospheres or microspheres, impregnated pads, solutions, sprays,
foams, sticks, soaps, shampoos or washing bases.
[0175] The concentration of compound of formula (I) in the cosmetic
composition is from 0.0001% to 2% by weight relative to the total
weight of the composition.
[0176] The pharmaceutical and cosmetic compositions as described
above may also contain inert or even pharmacodynamically active
additives as regards the pharmaceutical compositions, or
combinations of these additives, and especially: [0177] wetting
agents; [0178] flavor enhancers; [0179] preserving agents such as
para-hydroxybenzoic acid esters; [0180] stabilizers; [0181]
humidity regulators; [0182] pH regulators; [0183] osmotic pressure
modifiers; [0184] emulsifiers; [0185] UV-A and UV-B screening
agents; [0186] antioxidants, such as .alpha.-tocopherol,
butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase,
ubiquinol or certain metal-chelating agents; [0187] depigmenting
agents such as hydroquinone, azelaic acid, caffeic acid or kojic
acid; [0188] emollients; [0189] moisturizers, for instance
glycerol, PEG 400, thiamorpholinone and derivatives thereof, or
urea; [0190] anti-seborrhoeic or anti-acne agents, such as
S-carboxymethylcysteine, S-benzylcysteamine, salts thereof or
derivatives thereof, or benzoyl peroxide; [0191] antibiotics, for
instance erythromycin and its esters, neomycin, clindamycin and its
esters, and tetracyclines; [0192] anti-fungal agents such as
ketoconazole or polymethylene-4,5-isothiazolidones-3; [0193] agents
for promoting regrowth of the hair, for instance Minoxidil
(2,4-diamino-6-piperidinopyrimidine 3-oxide) and its derivatives,
Diazoxide (7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1-dioxide)
and Phenyloin (5,4-diphenylimidazolidine-2,4-dione); [0194]
non-steroidal anti-inflammatory agents; [0195] carotenoids, and
especially .beta.-carotene; [0196] anti-psoriatic agents such as
anthralin and its derivatives; [0197] eicosa-5,8,11,14-tetraynoic
acid and eicosa-5,8,11-triynoic acid, and esters and amides
thereof; [0198] retinoids, i.e., RAR or RXR receptor ligands, which
may be natural or synthetic; [0199] corticosteroids or oestrogens;
[0200] .alpha.-hydroxy acids and .alpha.-keto acids or derivatives
thereof, such as lactic acid, malic acid, citric acid, glycolic
acid, mandelic acid, tartaric acid, glyceric acid or ascorbic acid,
and also the salts, amides or esters thereof, or .beta.-hydroxy
acids or derivatives thereof, such as salicylic acid and the salts,
amides or esters thereof; [0201] ion-channel blockers such as
potassium-channel blockers; [0202] or alternatively, more
particularly for the pharmaceutical compositions, in combination
with medicinal products known to interfere with the immune system
(for example cyclosporin, FK 506, glucocorticoids, monoclonal
antibodies, cytokines or growth factors, etc.).
[0203] Of course, one skilled in this art will take care to select
the optional compound(s) to be added to these compositions such
that the advantageous properties intrinsically associated with the
present invention are not, or are not substantially, adversely
affected by the envisaged addition.
[0204] This invention also features a cosmetic regime or regimen
for beautifying the skin, wherein a composition comprising at least
one compound of formula (I) as defined above is applied to the
skin. Regulation and/or restoration of the metabolism of the skin
lipids makes it possible to obtain skin whose surface appearance is
embellished.
[0205] In order to further illustrate the present invention and the
advantages thereof, the following examples of specific active
compounds are given, as are the biological activities of such
compounds and specific formulations thereof, it being understood
that same are intended only as illustrative and in nowise
limitative. In said examples to follow, all parts and percentages
are given by weight, unless otherwise indicated.
Example 1
Synthesis of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylic
acid
##STR00005##
[0206] a. Preparation of N-methyloctanamide
[0207] 25 g (0.37 mol) of methylamine hydrochloride are dissolved
in 125 mL of dichloromethane, and 115 mL of triethylamine are then
added. At 0.degree. C., 70 mL (0.41 mol) of octanoyl chloride are
added slowly. The reaction mixture is stirred for 3 hours at room
temperature. The mixture is filtered and 100 ml of water are then
added to the filtrate. The organic phase is separated out by
settling, dried over sodium sulfate and evaporated. 61 g of
N-methyloctanamide are obtained in quantitative yield.
b. Preparation of N-methyl-N-(3-bromobenzyl)octanamide
[0208] 5 g (31.8 mmol) of N-methyloctanamide (1a) are added at
0.degree. C. to a suspension of 1.4 g (35 mmol) of sodium hydride
(60% in grease) in 60 mL of tetrahydrofuran. The reaction mixture
is stirred for 30 minutes at room temperature and a solution of 8.9
g (35 mmol) of 3-bromobenzyl bromide in 15 mL of tetrahydrofuran is
then added. The mixture is stirred for 16 hours at room
temperature. The reaction is stopped by adding 100 mL of water and
is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (75/25
heptane/ethyl acetate). 7.4 g of
N-methyl-N-(3-bromobenzyl)octanamide are obtained. Yield=71%.
c. Preparation of
octanoylmethyl-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzyl]am-
ide
[0209] g (3.98 mmol, 1.3 eq) of pinacoldiborane is added to a
mixture of 1.0 g (3.06 mmol, 1 eq) of N-methyl-N-(3-bromobenzyl)
octanamide and 900 mg (9.18 mmol, 3 eq) of potassium acetate, in
the presence of 111 mg (0.15 mmol, 5 mol %) of
diphenylphosphinoferrocenepalladium dichloride (PdCl.sub.2dppf) in
10 mL of dimethylformamide. The mixture is stirred for 2 hours at
80.degree. C. The reaction is stopped by adding 20 ml of water and
is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (80/20
heptane/ethyl acetate). 1.0 g of
octanoylmethyl-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzyl]ami-
de is obtained in the form of an oil. Yield=88%.
f. Preparation of methyl 3-(5-bromothiophen-2-yl)acrylate
[0210] 4.2 g (12.5 mmol, 1.2 eq) of methyl
triphenylphosphoranylideneacetate are added to a solution of 2.0 g
(10.4 mmol, 1.0 eq) of 5-bromothiophene-2-carbaldehyde in 15 mL of
toluene. The reaction mixture is stirred for 1 hour at 80.degree.
C. The reaction is stopped by adding 20 ml of water and is then
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (80/20 heptane/ethyl
acetate). 2.1 g of methyl 3-(5-bromothiophen-2-yl)acrylate are
obtained. Yield=82%.
g. Preparation of methyl
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylate
[0211] 200 mg (0.81 mmol, 1.0 eq) of methyl
3-(5-bromothiophen-2-yl)acrylate and 334 mg (0.89 mmol, 1.1 eq) of
octanoylmethyl-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzyl]ami-
de are dissolved in 5 ml of a 5/1 mixture of dimethylformamide and
of 2M potassium phosphate solution. 93 mg (0.08 mmol, 10 mol %) of
tetrakis(triphenylphosphine)palladium are added and the reaction
mixture is then stirred for 2 hours at 80.degree. C. The reaction
is stopped by adding 30 mL of water and is then extracted with
ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (80/20 to 60/40 heptane/ethyl
acetate). 220 mg of methyl
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylate
are obtained. Yield=65%.
h. Synthesis of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylic
acid
[0212] 212 mg (5.3 mmol, 10 eq) of sodium hydroxide are added to a
solution of 220 mg (0.53 mmol, 1 eq) of methyl
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylate
in 4 ml of 9/1 tetrahydrofuran/methanol. The reaction mixture is
stirred for two hours at room temperature. The reaction is stopped
by adding 20 ml of water and 3 ml of acetic acid and is then
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (90/10
dichloromethane/methanol). The oil obtained is crystallized from
pentane. 155 mg of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylic
acid are obtained. Yield=73%. m.p.=102-104.degree. C.
[0213] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (m, 3H); 1.31 (m,
8H); 1.72 (m, 2H); 2.42 (m, 2H); 2.98&3.00 (2s(rotamers), 3H);
4.60&4.66 (2s(rotamers), 2H); 6.24&6.26 (2d(rotamers),
J=15.6 Hz, 1H); 7.16-7.56 (m, 6H); 7.86 (2d(rotamers), J=15.6 Hz,
1H).
Example 2
Synthesis of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)propanoic
acid
##STR00006##
[0215] A solution of 80 mg (0.20 mmol, 1 eq) of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)acrylic
acid (prepared as in 1 h) in 2 mL of methanol is stirred for 2
hours at room temperature in the presence of 50 mg of 10% Pd/C
under a hydrogen atmosphere. The palladium is filtered off and the
solvents are then evaporated off. The residue is crystallized from
pentane/dichloromethane. 71 mg of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}thiophen-2-yl)propan-
oic acid are obtained. Yield=89%. m.p.=67-68.degree. C.
[0216] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (m, 3H); 1.28 (m,
8H); 1.70 (m, 2H); 2.41 (m, 2H); 2.78 (m, 2H); 2.96&2.98
(2s(rotamers), 3H); 3.18 (m, 2H); 4.57&4.63 (2s(rotamers), 2H);
6.82 (m, 1H); 7.05-7.14 (m, 2H); 7.28-7.48 (m, 3H).
Example 3
Synthesis of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylic
acid
##STR00007##
[0217] a. Preparation of methyl 3-(5-bromofuran-2-yl)acrylate
[0218] 4.58 g (13.7 mmol, 1.2 eq) of methyl
triphenylphosphoranylideneacetate are added to a solution of 2.0 g
(11.4 mmol, 1.0 eq) of 5-bromofuran-2-carbaldehyde in 15 mL of
toluene. The reaction mixture is stirred for 1 hour at 80.degree.
C. The reaction is stopped by adding 20 ml of water and is then
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (80/20 heptane/ethyl
acetate). 2.0 g of methyl 3-(5-bromofuran-2-yl)acrylate are
obtained. Yield=77%.
b. Preparation of methyl
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylate
[0219] 278 mg (1.20 mmol, 1.5 eq) of methyl
3-(5-bromofuran-2-yl)acrylate and 300 mg (0.80 mmol, 1.0 eq) of
octanoylmethyl-[3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzyl]ami-
de (prepared as in 1e) are dissolved in 5 ml of a 5/1 mixture of
dimethylformamide and of 2M potassium phosphate solution. 46 mg
(0.04 mmol, 5 mol %) of tetrakis(triphenylphosphine)palladium are
added and the reaction mixture is then stirred for 2 hours at
80.degree. C. The reaction is stopped by adding 30 ml of water and
is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (80/20 to
60/40 heptane/ethyl acetate). 250 mg of methyl
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylate are
obtained. Yield=78%.
c. Synthesis of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylic
acid
[0220] 300 mg (7.5 mmol, 12 eq) of sodium hydroxide are added to a
solution of 250 mg (0.63 mmol, 1 eq) of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylate in
4 mL of 9/1 tetrahydrofuran/methanol. The reaction mixture is
stirred for two hours at room temperature. The reaction is stopped
by adding 20 ml of water and 3 ml of acetic acid and is then
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (90/10
dichloromethane/methanol). The oil obtained is crystallized from
pentane. 140 mg of
3-(5-{3-[(methyloctanoylamino)methyl]phenyl}furan-2-yl)acrylic acid
are obtained. Yield=58%. m.p.=96-98.degree. C.
[0221] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (m, 3H); 1.28 (m,
8H); 1.71 (m, 2H); 2.42 (m, 2H); 2.98&3.00 (2s(rotamers), 3H);
4.61&4.67 (2s(rotamers), 2H); 6.43 (2d(rotamers), J=15.6 Hz,
1H); 6.76 (m, 2H); 7.18 (2d(rotamers), J=7.6 Hz, 1H); 7.37-7.69 (m,
4H).
Example 4
Synthesis of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylic
acid
##STR00008##
[0222] a. Preparation of
octanoyl(4-bromothiophen-2-ylmethyl)methylamide
[0223] 880 mg (13 mmol, 5 eq) of methylamine hydrochloride and 500
mg (2.61 mmol, 1 eq) of 4-bromothiophene-2-carbaldehyde are
dissolved in 5 ml of methanol in the presence of 2 g of anhydrous
magnesium sulfate. The reaction mixture is stirred for 1 hour at
room temperature. 327 mg (5.2 mmol, 2 eq) of sodium
cyanoborohydride are added and the reaction mixture is stirred for
4 hours at room temperature. The reaction is stopped by adding 20
ml of water and is then extracted with ethyl acetate. The organic
phases are combined and dried over sodium sulfate. The solvents are
evaporated off and the residue is then dissolved in 4 ml of
tetrahydrofuran in the presence of 0.5 mL of triethylamine. 0.45 mL
(2.6 mmol, 1 eq) of octanoyl chloride is added and the reaction
mixture is then stirred for 0.5 hour at room temperature. The
reaction is stopped by adding 20 mL of water and is then extracted
with ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (80/20 heptane/ethyl acetate).
300 mg of octanoyl(4-bromothiophen-2-ylmethyl)methylamide are
obtained. Yield=35%.
b. Preparation of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]acrylate
[0224] g (4.3 mmol, 1.1 eq) of pinacoldiborane are added to a
mixture of 1.0 g (3.9 mmol, 1 eq) of ethyl 4-bromocinnamate and 1.1
g (11.7 mmol, 3 eq) of potassium acetate in the presence of 142 mg
(0.19 mmol, 5 mol %) of diphenylphosphinoferrocenepalladium
dichloride (PdCl.sub.2dppf) in 10 mL of dimethylformamide. The
mixture is stirred for 2 hours at 70.degree. C. The reaction is
stopped by adding 20 ml of water and is then extracted with ethyl
acetate. The organic phases are combined and dried over sodium
sulfate. The solvents are evaporated off and the residue is then
chromatographed on silica gel (90/10 heptane/ethyl acetate). 1.15 g
of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]acrylate
are obtained in the form of an oil. Yield=98%.
c. Preparation of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylate
[0225] 300 mg (0.90 mmol, 1.0 eq) of
octanoyl(4-bromothiophen-2-ylmethyl)methylamide and 326 mg (1.08
mmol, 1.2 eq) of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]acrylate
are dissolved in 4 ml of a 5/1 mixture of dimethylformamide and of
2M potassium phosphate solution. 52 mg (0.04 mmol, 5 mol %) of
tetrakis(triphenylphosphine)palladium are added and the reaction
mixture is then stirred for 2 hours at 80.degree. C. The reaction
is stopped by adding 30 mL of water and is then extracted with
ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (80/20 to 60/40 heptane/ethyl
acetate). 250 mg of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylate
are obtained. Yield=65%.
d. Synthesis of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylic
acid
[0226] 230 mg (5.8 mmol, 10 eq) of sodium hydroxide are added to a
solution of 250 mg (0.58 mmol, 1 eq) of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylate
in 4 mL of 9/1 tetrahydrofuran/methanol. The reaction mixture is
stirred for 2 hours at room temperature. The reaction is stopped by
adding 20 mL of water and 3 mL of acetic acid and is then extracted
with ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (90/10
dichloromethane/methanol). The oil obtained is crystallized from
pentane. 80 mg of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)acrylic
acid are obtained. Yield=35%. m.p.=175.degree. C.
[0227] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (m, 3H); 1.33 (m,
8H); 1.70 (m, 2H); 2.38&2.48 (2t(rotamers), J=7.6 Hz, 2H);
3.05&3.06 (2s(rotamers), 3H); 4.71&4.76 (2s(rotamers), 2H);
6.47&6.49 (2d(rotamers), J=15.9 Hz, 1H); 6.76 (m, 2H); 7.28 (m,
1H); 7.44 (m, 1H); 7.60 (m, 4H); 7.80 (2d(rotamers), J=15.9 Hz,
1H).
Example 5
Synthesis of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoic
acid
##STR00009##
[0228] a. Preparation of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propanoate
[0229] A solution of 8 g (26.4 mmol) of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]acrylate
in 30 mL of methanol is stirred for one hour at room temperature in
the presence of 400 mg of 10% palladium-on-charcoal under a
hydrogen atmosphere. The catalyst is filtered off and the solvents
are then evaporated off. 7.8 g of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propanoate
are obtained. Yield=96%.
b. Preparation of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoate
[0230] 430 mg (1.29 mmol, 1 eq) of
octanoyl(4-bromothiophen-2-ylmethyl)methylamide and 470 mg (1.55
mmol, 1.2 eq) of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propanoate
are dissolved in 4 ml of a 6/1 mixture of dimethylformamide and of
2M potassium phosphate solution. 15 mg (0.064 mmol, 5 mol %) of
palladium acetate and 45 mg (0.129 mmol, 10 mol %) of dicyclohexyl
2-biphenylphosphine are added. The mixture is stirred for 2 hours
at 90.degree. C. The reaction is stopped by adding 30 mL of water
and is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (80/20 to
70/30 heptane/ethyl acetate). 245 mg of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoate
are obtained. Yield=44%.
c. Synthesis of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoic
acid
[0231] 100 mg (2.5 mmol, 4 eq) of sodium hydroxide are added to a
solution of 245 mg (0.57 mmol, 1 eq) of ethyl
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoate
in 4 mL of 9/1 tetrahydrofuran/methanol. The reaction mixture is
stirred for two hours at room temperature. The reaction is stopped
by adding 20 mL of water and 3 mL of acetic acid and is then
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (90/10
dichloromethane/methanol). The oil obtained is crystallized from
pentane. 85 mg of
3-(4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propanoic
acid are obtained. Yield=37%.
[0232] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.89 (m, 3H); 1.32 (m,
8H); 1.70 (m, 2H); 2.37&2.48 (2t(rotamers), J=7.2 Hz, 2H); 2.71
(t, 2H, J=7.6 Hz); 2.99 (m, 2H); 3.02 (s, 3H); 4.74&4.69
(2s(rotamers), 2H); 7.18-7.34 (m, 4H); 7.50 (d, J=3.2 Hz, 2H).
Example 6
Synthesis of
3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid
##STR00010##
[0233] a. Preparation of tert-butyl
(6-bromopyrid-2-yl)carbamate
[0234] 62 g (284 mmol) of di-tert-butyl dicarbonate diluted in 200
ml of dichloromethane are added dropwise to a solution of 49.2 g
(284 mmol) of 2-amino-6-bromopyridine, 43.4 ml (312 mmol) of
triethylamine and 3.5 g (28.4 mmol) of 4-dimethylaminopyridine in
400 ml of dichloromethane. The reaction medium is stirred at room
temperature for 18 hours. After addition of water and extraction
with dichloromethane, the organic phase is dried over magnesium
sulfate, filtered and evaporated. The residue obtained is purified
by chromatography on a column of silica eluted with a 95/5
heptane/ethyl acetate mixture. 39 g (50%) of tert-butyl
(6-bromopyrid-2-yl)carbamate are obtained in the form of a white
solid.
b. Preparation of tert-butyl
6-bromopyrid-2-yl-N-methylcarbamate
[0235] To a solution of 39 g (14.3 mmol) of tert-butyl
(6-bromopyrid-2-yl)carbamate in 400 ml of dimethylformamide are
added portionwise 6.9 g (17.2 mmol) of 60% sodium hydride in oil.
After stirring for 20 minutes at room temperature, 17.8 ml (28.6
mmol) of methyl iodide are added dropwise. The reaction medium is
stirred at room temperature for 18 hours, taken up in water and
extracted with ethyl acetate. The organic phase is dried over
magnesium sulfate, filtered and evaporated.
c. Preparation of ethyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}acrylate
[0236] 1.25 g (4.13 mmol, 1.2 eq) of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]acrylate
and 1.0 g (3.48 mmol, 1 eq) of tert-butyl
(6-bromopyrid-2-yl)-methylcarbamate are dissolved in 15 ml of a 6/1
mixture of dimethylformamide and of 2M potassium phosphate
solution. 200 mg (0.173 mmol, 5 mol %) of
tetrakis(triphenylphosphine)palladium are added. The mixture is
stirred for 3 hours at 90.degree. C. The reaction is stopped by
adding 30 mL of water and is then extracted with ethyl acetate. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (80/20 to 70/30 heptane/ethyl acetate). 850 mg of
ethyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}acrylate
are obtained. Yield=64%.
d. Preparation of ethyl
3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}acrylate
[0237] 300 mg (0.78 mmol) of ethyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}acrylate
are dissolved in 5 mL of dichloromethane. 2 mL of trifluoroacetic
acid are added. The reaction mixture is stirred for 3 hours at room
temperature. The reaction is stopped by adding 30 mL of saturated
sodium hydrogen carbonate solution and is then extracted with ethyl
acetate. The organic phases are combined and dried over sodium
sulfate. The solvents are evaporated off and the oil obtained is
then dissolved in 5 ml of dichloromethane in the presence of 1 ml
of triethylamine. 630 .mu.L (3.9 mmol, 5 eq) of heptyl isocyanate
are added along with 100 mg of dimethylaminopyridine. The reaction
mixture is stirred for 16 hours at reflux. The reaction is stopped
by adding 30 mL of water and is then extracted with ethyl acetate.
The organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (80/20 to 70/30 heptane/ethyl acetate). 170 mg of
ethyl 3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}acrylate
are obtained. Yield=51%.
e. Synthesis of
3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid
[0238] 170 mg (0.4 mmol) of ethyl
3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}acrylate are
dissolved in 5 ml of methanol. 50 mg of 10% palladium-on-charcoal
are added. The reaction mixture is stirred for 3 hours at room
temperature under a hydrogen atmosphere. The catalyst is filtered
off and the solvents are then evaporated off and the oil obtained
is used directly in the following reaction. 170 mg of sodium
hydroxide are added to the solution of ethyl
3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoate in 5
ml of 9/1 tetrahydrofuran/methanol. The reaction mixture is stirred
for two hours at room temperature. The reaction is stopped by
adding 20 mL of water and 3 mL of acetic acid and is then extracted
with ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (7/3 to 1/1 heptane/EtOAc). 110
mg of 3-{4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoic
acid are obtained. Yield=69% over two steps. m.p.=108.degree.
C.
[0239] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.87 (t, J=7.0 Hz, 3H);
1.20-1.36 (m, 8H); 1.61 (m, 2H); 2.76 (t, J=7.7 Hz, 2H); 3.06 (t,
2H, J=7.7 Hz); 3.38 (q, J=5.5 Hz, 2H); 3.47 (s, 3H); 6.94 (d, J=8.4
Hz, 1H); 7.35 (m, 3H); 7.76 (t, J=7.8 Hz, 1H); 7.81 (d, J=8.0 Hz,
2H); 10.48 (s, 1H).
Example 7
Synthesis of
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-2-yl}propanoic
acid
##STR00011##
[0240] a. Preparation of tert-butyl (3-bromophenyl)carbamate
[0241] To a mixture of 94 g (549 mmol) of 3-bromoaniline and 11 of
dichloromethane are added portionwise, at room temperature, 120 g
(549 mmol) of di-tert-butyl dicarbonate. After stirring for 18
hours, the reaction medium is poured into ice-water and then
extracted with dichloromethane. The organic phase is separated out
by settling of the phases, dried over magnesium sulfate and
evaporated. 138 g of tert-butyl (3-bromophenyl)carbamate are
obtained in a yield of 98%.
b. Preparation of tert-butyl (3-bromophenyl)-N-methylcarbamate
[0242] To a solution of 114 g (447 mmol) of tert-butyl
(3-bromophenyl)carbamate in 800 ml of DMF are added portionwise 19
g (475 mmol) of sodium hydride (60% in oil) and the reaction medium
is stirred until the evolution of gas has ceased. 29.3 ml (470
mmol) of methyl iodide are added dropwise and stirring is continued
for 18 hours. The reaction medium is poured into ice-water and
extracted with ethyl acetate. The organic phase is separated out by
settling of the phases, dried over magnesium sulfate and
evaporated. 115 g of tert-butyl (3-bromophenyl)-N-methylcarbamate
are obtained in a yield of 95%.
c. Preparation of (3-bromophenyl)methylamine
[0243] 5 ml of trifluoromethanesulfonic acid are added to a
solution of 3.6 g (12.7 mmol) of tert-butyl
(3-bromophenyl)-N-methylcarbamate in 15 mL of dichloromethane. The
reaction medium is stirred for 1 hour at room temperature (RT). The
reaction is stopped by adding 50 ml of saturated sodium hydrogen
carbonate solution and then extracted with ethyl acetate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel, eluting with 1/1 heptane/ethyl acetate. 2.14 g of
oil are obtained. 90% yield.
d. Preparation of N-methyl-3-aminophenylboronic acid
[0244] 37.6 g (202 mmol, 1 eq) of (3-bromophenyl)methylamine
[0245] (obtained as in 1c) are dissolved in 300 mL of
tetrahydrofuran. The reaction mixture is cooled to -70.degree. C.
and 166 mL (242 mmol, 1.2 eq) of 1.5 M methyllithium are then added
slowly, while keeping the temperature at -70.degree. C. The
reaction mixture is stirred for 1 hour at -70.degree. C. 306 mL
(444 mmol, 2.2 eq) of 1.46 M tert-butyllithium are added, while
keeping the temperature at -70.degree. C. The reaction mixture is
stirred for 45 minutes at -70.degree. C. 103.5 ml (808 mmol, 4 eq)
of trimethyl borate are added at -65.degree. C. and the reaction
mixture is then warmed to room temperature. The reaction is stopped
by adding 1 L of 1N hydrochloric acid. The pH is adjusted to pH 5
and the reaction medium is then extracted with n-butanol. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (70/30 heptane/ethyl acetate). 11.3 g of
N-methyl-3-aminophenylboronic acid are obtained. Yield=40%.
e. Preparation of [3-(5-bromopyrid-2-yl)phenyl]methylamine
[0246] 2.2 g (9.5 mmol, 1.2 eq) of 2,5-dibromopyridine are
dissolved in 3 mL of an 8/2 mixture of dimethylformamide/2M
potassium phosphate. 1.2 g (7.9 mmol, 1 eq) of
N-methyl-3-aminophenylboronic acid are added along with 456 mg
(0.39 mmol, 5 mol %) of tetrakis(triphenylphosphine)palladium. The
mixture is stirred for 3 hours at 90.degree. C. The reaction is
stopped by adding 30 mL of water and is then extracted with ethyl
acetate. The organic phases are combined and dried over sodium
sulfate. The solvents are evaporated and the residue is then
chromatographed on silica gel (80/20 to 70/30 heptane/ethyl
acetate). 1.07 g of [3-(5-bromopyrid-2-yl)phenyl]methylamine are
obtained. Yield=52%.
f. Preparation of
tert-butyl[3-(5-bromopyrid-2-yl)phenyl}methylcarbamate
[0247] 1.07 g (4 mmol, 1 eq) of
[3-(5-bromopyrid-2-yl)phenyl]methylamine are dissolved in 10 mL of
dichloromethane in the presence of 1 mL of triethylamine and 200 mg
of dimethylaminopyridine. 1.7 g (8 mmol, 2 eq) of tert-butyl
dicarbonate are added and the reaction mixture is stirred overnight
at 40.degree. C. The reaction is stopped by adding 30 ml of water
and is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (70/30
heptane/ethyl acetate). 1.18 g of
tert-butyl[3-(5-bromopyrid-2-yl)phenyl]methylcarbamate are
obtained. Yield=81%.
g. Preparation of ethyl
3-{6-[3-(tert-butoxycarbonylmethylamino)phenyl}pyrid-3-yl}acrylate
[0248] 1.18 g of
tert-butyl[3-(5-bromopyrid-2-yl)phenyl]methylcarbamate (3.25 mmol,
1 eq) are dissolved in 10 mL of dimethylformamide and 1 ml of
triethylamine. 110 mg (0.48 mmol, 15%) of palladium acetate and 296
mg (0.96 mmol, 30%) of o-tolylphosphine are added, along with 1 mL
of ethyl acrylate. The reaction mixture is stirred overnight at
80.degree. C. The reaction is stopped by adding 30 ml of water and
is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off and the residue is then chromatographed on silica gel (70/30
heptane/ethyl acetate). 852 mg of ethyl
3-{6-[3-(tert-butoxycarbonylmethylamino)phenyl}pyrid-3-yl}acrylate
are obtained. Yield=68%.
h. Preparation of ethyl
3-[6-(3-methylaminophenyl)pyrid-3-yl]propanoate
[0249] A solution of 852 mg (2.23 mmol) of ethyl
3-{6-[3-(tert-butoxycarbonylmethylamino)phenyl}pyrid-3-yl}acrylate
in 10 mL of methanol is stirred for 4 hours at room temperature in
the presence of 100 mg of 10% palladium-on-charcoal under a
hydrogen atmosphere. The catalyst is filtered off and the solvents
are then evaporated off. The oil obtained is dissolved in 15 mL of
dichloromethane. 2 mL of trifluoroacetic acid are added and the
reaction mixture is stirred for 4 hours at room temperature. The
reaction is stopped by adding 100 mL of saturated sodium hydrogen
carbonate solution and is then extracted with ethyl acetate. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (70/30 heptane/ethyl acetate). 710 mg of ethyl
3-[6-(3-methylaminophenyl)pyrid-3-yl]propanoate are obtained.
Yield=68%.
i. Preparation of ethyl
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoate
[0250] 572 .mu.L (3.5 mmol, 2 eq) of heptyl isocyanate are added to
a solution of 500 mg (1.76 mmol, 1 eq) of ethyl
3-[6-(3-methylaminophenyl)pyrid-3-yl]propanoate in 10 mL of a 4/1
tetrahydrofuran/triethylamine mixture. The reaction mixture is
stirred for 24 hours at 40.degree. C. The reaction is stopped by
adding 30 ml of water and is then extracted with ethyl acetate. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (70/30 heptane/ethyl acetate). 488 mg of ethyl
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoate are
obtained. Yield=65%.
j. Synthesis of
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoic
acid
[0251] 200 mg (5 mmol, 4 eq) of sodium hydroxide are added to a
solution of 488 mg (1.14 mmol, 1 eq) of ethyl
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoate in 6
mL of 9/1 tetrahydrofuran/methanol. The reaction mixture is stirred
for 3 hours at room temperature. The reaction is stopped by adding
20 ml of water and 3 ml of acetic acid and is then extracted with
ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then chromatographed on silica gel (70/30 to 50/50 heptane/ethyl
acetate). The oil obtained is crystallized from pentane. 442 mg of
3-{6-[3-(3-heptyl-1-methylureido)phenyl]pyrid-3-yl}propanoic acid
are obtained. Yield=94%. m.p.=118.degree. C.
[0252] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.85 (t, J=6.8 Hz, 3H);
1.25 (m, 8H); 1.40 (m, 2H); 2.74 (t, J=7.4 Hz, 2H); 3.05 (t, J=7.3
Hz, 2H); 3.17 (q, J=6.0 Hz, 2H); 3.32 (s, 3H); 4.42 (m, 1H); 7.29
(m, 1H); 7.52 (t, J=8.0 Hz, 1H); 7.66 (m, 2H); 7.86 (m, 2H); 8.63
(m, 1H).
Example 8
Synthesis of
2-[4-(2-carboxyethyl)phenyl]-4-(3-heptyl-1-methylureido)pyridinium
acetate
##STR00012##
[0253] a. Preparation of tert-butyl
(2-chloropyrid-4-yl)carbamate
[0254] 1.69 g (7.78 mmol, 1 eq) of tert-butyl dicarbonate dissolved
in 50 ml of dichloromethane, in the presence of 95 mg of
dimethylaminopyridine, are added to a solution of 1 g (7.78 mmol, 1
eq) of 4-amino-2-chloropyridine in 30 mL of dichloromethane in the
presence of 1.19 mL (1.19 mmol, 1.1 eq) of triethylamine. The
reaction mixture is stirred overnight at room temperature. The
reaction is stopped by adding 100 ml of water and is then extracted
with dichloromethane. The organic phases are combined and dried
over sodium sulfate. The solvents are evaporated off and the
residue is then chromatographed on silica gel (70/30 to 50/50
heptane/ethyl acetate). The oil obtained is crystallized from
pentane. 1.40 g of tert-butyl (2-chloropyrid-4-yl)carbamate are
obtained. Yield=80%.
b. Preparation of tert-butyl
(2-chloropyrid-4-yl)methylcarbamate
[0255] A solution of 17.5 g (76.7 mmol, 1 eq) dissolved in 100 ml
of dimethylformamide is added to a suspension of 3.57 g (92 mmol,
1.2 eq) of sodium hydride in 100 mL of dimethylformamide at
0.degree. C. The reaction mixture is stirred for 30 minutes at room
temperature. 9.26 ml (148 mmol, 2 eq) of methyl iodide are added to
the reaction mixture and the reaction medium is then stirred for 2
hours at room temperature. The reaction is stopped by adding 100 mL
of water and is then extracted with ethyl acetate. The organic
phases are combined and dried over sodium sulfate. The solvents are
evaporated off. 18 g of tert-butyl
(2-chloropyrid-4-yl)methylcarbamate are obtained. Yield=97%.
c. Preparation of ethyl
3-{4-[4-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}propanoate
[0256] 500 mg (2.06 mmol, 1 eq) of tert-butyl
(2-chloropyrid-4-yl)methylcarbamate and 750 mg (2.47 mmol, 1.2 eq)
of ethyl
3-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]propanoate
(obtained as in 5a) are dissolved in 10 mL of an 8/2 mixture of
dimethylformamide/2M potassium phosphate. 23 mg (0.123 mmol, 5 mol
%) of palladium acetate and 71 mg (0.24 mmol, 10 mol %) of
dicyclohexyldiphenylphosphine are added. The mixture is stirred for
4 hours at 90.degree. C. The reaction is stopped by adding 30 ml of
water and is then extracted with ethyl acetate. The organic phases
are combined and dried over sodium sulfate. The solvents are
evaporated off and the residue is then chromatographed on silica
gel (80/20 to 70/30 heptane/ethyl acetate). 415 mg of ethyl
3-{4-[4-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}propanoate
are obtained. Yield=52%.
d. Preparation of ethyl
3-[4-(4-methylaminopyrid-2-yl)phenyl]propanoate
[0257] 415 mg (1.08 mmol, 1 eq) of ethyl
3-{4-[4-(tert-butoxycarbonylmethylamino)pyrid-2-yl]phenyl}propanoate
are dissolved in 10 mL of dichloromethane. 3 mL of trifluoroacetic
acid are added and the reaction mixture is stirred for 4 hours at
room temperature. The reaction is stopped by adding 100 mL of
saturated sodium hydrogen carbonate solution and is then extracted
with ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off. 270 mg of ethyl
3-[4-(4-methylaminopyrid-2-yl)phenyl]propanoate are obtained.
Yield=88%.
e. Preparation of ethyl
3-{4-[4-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoate
[0258] 270 mg (0.63 mmol, 1 eq) of ethyl
3-[4-(4-methylaminopyrid-2-yl)phenyl]propanoate are mixed with 0.6
mL (3.7 mmol, 6 eq) of heptyl isocyanate and then irradiated in a
microwave machine for 2 times 30 minutes, while keeping the
temperature constant at 100.degree. C. The reaction mixture is
chromatographed on silica gel (90/10 heptane/ethyl acetate). 260 mg
of ethyl
3-{4-[4-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoate are
obtained. Yield=64%.
f. Synthesis of
2-[4-(2-carboxyethyl)phenyl]-4-(3-heptyl-1-methylureido)pyridinium
acetate
[0259] 100 mg (2.5 mmol, 4 eq) of sodium hydroxide are added to a
solution of 260 mg (0.61 mmol, 1 eq) of ethyl
3-{4-[4-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propanoate in 5
ml of 9/1 tetrahydrofuran/methanol. The reaction mixture is stirred
for two hours at room temperature. The reaction is stopped by
adding 20 mL of water and 3 mL of acetic acid and is then extracted
with ethyl acetate. The organic phases are combined and dried over
sodium sulfate. The solvents are evaporated off and the residue is
then crystallized from pentane. 143 mg of
2-[4-(2-carboxyethyl)phenyl]-4-(3-heptyl-1-methylureido)pyridinium
acetate are obtained. Yield=59%. m.p.=71-73.degree. C.
[0260] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (t, J=7.2 Hz, 3H);
1.32 (m, 8H); 1.58 (m, 2H); 2.11 (s, 3H); 2.70 (t, J=6.9 Hz, 2H);
3.00 (t, J=6.9 Hz, 2H); 3.29 (q, J=6.3 Hz, 2H); 3.38 (s, 3H); 6.14
(m, 1H); 7.12 (d, J=5.6 Hz, 1H); 7.31 (d, J=7.6 Hz, 2H); 7.51 (s,
1H); 7.79 (d, J=7.6 Hz, 2H); 8.43 (d, J=5.5 Hz, 1H).
Example 9
Synthesis of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl)acrylic
acid
##STR00013##
[0261] a. Preparation of
3-(N-methyl-N-tert-butoxycarbonyl)phenylboronic acid
[0262] 18.5 ml (46.2 mmol, 1.3 eq) of 2.5M butyllithium in hexane
are added to a solution of 10 g (34.9 mmol, 1 eq) of tert-butyl
(3-bromophenyl)methylcarbamate (obtained as in 7b) in 25 mL of
tetrahydrofuran cooled to -78.degree. C. The reaction mixture is
stirred for 30 minutes at -78.degree. C. and 10 mL (41.9 mmol, 1.2
eq) of diisopropyl borate are then added dropwise. The reaction
mixture is stirred at -78.degree. C. for 2 hours. The reaction is
stopped by adding 70 ml of 1N hydrochloric acid at -10.degree. C.,
and is then extracted with ethyl acetate. The organic phases are
combined and dried over sodium sulfate. The solvents are evaporated
off. 9.17 g of 3-(N-methyl-N-tert-butoxycarbonyl)phenylboronic acid
are obtained in a crude yield of 100%.
b. Preparation of
tert-butyl[3-(2-bromopyrimidin-5-yl)phenyl]methylcarbamate
[0263] 22 ml of 2M potassium carbonate (43.9 mmol, 2.5 eq) are
added dropwise to a solution of
3-(N-methyl-N-tert-butoxycarbonyl)phenylboronic acid (5.3 g, 21.06
mmol, 1.2 eq) and 5-bromo-2-iodopyrimidine (5 g, 17.6 mmol, 1 eq)
in 50 ml of diethyl ether. The reaction medium is degassed with
nitrogen for 30 minutes and tetrakis(triphenylphosphine)palladium
(1.01 g, 0.88 mmol, 0.05 eq) is then added. The reaction mixture is
stirred overnight at 100.degree. C. The reaction is stopped by
adding water and is then extracted with ethyl acetate. The solvents
are evaporated off and the residue is then chromatographed on
silica gel (90/10 heptane/ethyl acetate). 1.87 g of
tert-butyl[3-(2-bromopyrimidin-5-yl)phenyl]methylcarbamate are
obtained in the form of a beige-colored solid in a yield of
30%.
c. Preparation of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}acrylate
[0264] 0.25 ml (2.75 mmol, 2 eq) of methyl acrylate, 9.3 mg (0.04
mmol, 0.3 eq) of palladium acetate and 25 mg (0.08 mmol, 0.06 eq)
of tri-ortho-tolylphosphine are added to a solution of 0.5 g (1.37
mmol, 1 eq) of
tert-butyl[3-(2-bromopyrimidin-5-yl)phenyl]methylcarbamate in 0.5
ml of dimethylformamide. The reaction mixture is heated at
80.degree. C. overnight. The reaction is stopped by adding 20 ml of
water and is then extracted with ethyl acetate. The organic phases
are combined and dried over sodium sulfate. The solvents are
evaporated off and the residue is then chromatographed on silica
gel (95/5 heptane/ethyl acetate). 377.7 mg of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}a-
crylate are obtained in the form of a beige-colored solid.
Yield=75%.
d. Preparation of methyl
3-(3'-methylaminobiphenyl-4-yl)acrylate
[0265] 0.16 ml (2.04 mmol, 5 eq) of trifluoroacetic acid is added
to a solution of 151 mg (0.4 mmol, 1 eq) of methyl
3-{5'-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}acrylate
in 3 ml of dichloromethane. The reaction mixture is stirred for
eight hours at room temperature. The reaction is stopped by adding
aqueous ammonia solution and is then extracted with ethyl acetate.
The organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then taken up in
heptane. 71.6 mg of methyl 3-(3'-methylaminobiphenyl-4-yl)acrylate
are obtained in the form of a yellow solid. Yield=65%.
e. Preparation of methyl
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidine-2-acrylate
[0266] 22 .mu.L (0.53 mmol, 1 eq) of pentyl isocyanate are added
dropwise to a solution of 71.6 mg (0.27 mmol, 1 eq) of methyl
3-[5-(3-methylaminophenyl)pyrimidin-2-yl]acrylate and 22 .mu.L of
triethylamine in 2 mL of dichloromethane. The reaction mixture is
stirred for 2 days at room temperature. The reaction is stopped by
adding 10 ml of water and is then extracted with ethyl acetate. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on silica gel (70/30 heptane/ethyl acetate). 37.6 mg of methyl
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidine-2-acrylate are
obtained in the form of white crystals. Yield=38%.
f. Synthesis of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}acrylic
acid
[0267] 10 mg (242.5 .mu.mol, 2.5 eq) of sodium hydroxide pellets
are added to a solution of 37.6 mg (97 .mu.mol, 1 eq) of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidine-2-acrylate in 2
ml of tetrahydrofuran and 4 drops of water. The reaction mixture is
stirred for 8 hours at room temperature. The reaction medium is
concentrated and then diluted with 10 ml of water and washed with
twice 10 ml of dichloromethane. The aqueous phase is acidified with
1N hydrochloric acid and then extracted with ethyl acetate. The
organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then chromatographed
on a preparative silica plate (95/5/0.5%
dichloromethane/methanol/aqueous ammonia). 7.9 mg of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}acrylic acid
are obtained in the form of beige-colored crystals. Yield=22%.
[0268] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.88 (t, J=7 Hz, 3H);
1.27 (m, 4H); 1.42 (m, 2H); 3.18 (q, j=6.8 Hz, 2H); 3.37 (s, 3H);
4.41 (t, J=5.5 Hz, 1H); 6.67 (d, J=16.2 Hz, 1H); 7.44 (d, J=7.8 Hz,
1H); 7.58 (t, J=7.8 Hz, 1H); 7.76 (d, J=16.2 Hz, 1H); 8.42 (m, 2H);
8.99 (s, 2H).
Example 10
Synthesis of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoic
acid
##STR00014##
[0269] a. Preparation of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}propanoate
[0270] 30 mg of 10% Pd/C are added to a solution of 0.3 g (0.81
mmol, 1 eq) of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}acrylate
(obtained as in 9c) in 3 ml of methanol, in a PARR bomb. The
reaction mixture is placed under a hydrogen pressure of 3 bar and
is then heated at 50.degree. C. for 12 hours. The reaction medium
is cooled to room temperature and then degassed with nitrogen and
filtered through Celite. After evaporating off the solvents, the
residue is chromatographed on silica gel (90/10 heptane/ethyl
acetate). 118.2 mg of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}propanoate
are obtained in the form of a colorless oil. Yield=40%.
b. Preparation of methyl
3-[5-(3-methylaminophenyl)pyrimidin-2-yl]propanoate
[0271] 0.12 ml (1.6 mmol, 5 eq) of trifluoroacetic acid is added to
a solution of 118 mg (0.32 mmol, 1 eq) of methyl
3-{5-[3-(tert-butoxycarbonylmethylamino)phenyl]pyrimidin-2-yl}propanoate
in 4 ml of dichloromethane. The reaction mixture is stirred for 16
hours at room temperature. The reaction is stopped by adding 20 mL
of 1N sodium hydroxide solution and is then extracted with ethyl
acetate. The organic phases are combined and dried over sodium
sulfate. The solvents are evaporated off and the residue is then
chromatographed on silica gel (99/1 dichloromethane/methanol). 163
mg of methyl 3-[5-(3-methylaminophenyl)pyrimidin-2-yl]propanoate
are obtained in the form of a colorless oil. Yield=99%.
c. Preparation of methyl
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoate
[0272] 133 mg (0.66 mmol, 1.1 eq) of 4-nitrophenyl chloroformate
are added to a solution, cooled to 0.degree. C., of 163 mg (0.6
mmol, 1 eq) of 3-[5-(3-methylaminophenyl)pyrimidin-2-yl]propanoate
and 0.1 ml (0.72 mmol, 1.2 eq) in 5 ml of dichloromethane. The
reaction mixture is stirred for 12 hours at room temperature. The
reaction is stopped by adding 20 ml of water, dried over sodium
sulfate and filtered, and the solvents are evaporated off. The
residue is taken up in 3 ml of dimethylformamide and 69 .mu.l (0.6
mmol, 1 eq) of N-amylamine are then added. The reaction medium is
heated at 80.degree. C. for 4 hours and then poured onto ice and
extracted with ethyl acetate. The organic phases are combined and
dried over sodium sulfate, the solvents are concentrated and the
residue is then chromatographed on silica gel (60/40 heptane/ethyl
acetate).
[0273] 111.9 mg of methyl
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoate
are obtained in the form of a yellow oil. Yield=48%.
d. Synthesis of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoic
acid
[0274] 1.44 ml (1.45 mmol, 5 eq) of lithium hydroxide are added to
a solution of 111 mg (0.29 mmol, 1 eq) of methyl
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoate
in 3 mL of tetrahydrofuran. The reaction mixture is stirred for
four hours at room temperature. The reaction is stopped by adding
10 ml of water, washed with ether and then acidified with 1N
hydrochloric acid solution, and then extracted with ethyl acetate.
The organic phases are combined and dried over sodium sulfate. The
solvents are evaporated off and the residue is then crystallized
from ether. 66.7 mg of
3-{5-[3-(1-methyl-3-pentylureido)phenyl]pyrimidin-2-yl}propanoic
acid are obtained in the form of white crystals. Yield=48%.
[0275] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.84 (t, J=7.0 Hz, 3H);
1.25 (m, 4H); 1.39 (m, 2H); 2.78 (t, J=7.3 Hz, 2H); 3.03 (t, J=7.1,
2H); 3.17 (q, J=7.2 Hz, 2H); 3.19 (s, 3H); 4.41 (t, J=5.4 Hz, 1H);
7.38 (m, 1H); 7.55 (t, J=8 Hz, 1H); 8.35 (m, 2H); 8.75 (s, 2H).
Example 11
Synthesis of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-pentylureido)pyridini-
um hydrochloride
##STR00015##
[0276] a. Preparation of 6-methylamino-2-bromopyridine
[0277] 30 g (0.13 mol) of 2,6-dibromopyridine are added to a
solution of 225 ml (2.39 mol) of methylamine in ethanol (33% by
weight, Aldrich) precooled to 0.degree. C. The reaction is heated
at 80.degree. C. with stirring for 20 hours, in a glass system
equipped with a manometer. The reaction is monitored by TLC
control. The reaction medium is cooled to 0.degree. C. and the
assembly is opened. The slightly brown solution thus obtained is
concentrated under vacuum to a volume of 60 ml, and water (240 ml)
is then added, followed by addition of aqueous sodium carbonate
solution (2N, 240 ml). The beige-coloured precipitate formed is
filtered off, washed with water and dissolved in dichloromethane
(200 ml). The solution is dried over magnesium sulfate and the
solvent is evaporated off. The addition of heptane allows the
precipitation of 17.5 g (74%) of 6-methylamino-2-bromopyridine in
the form of a beige-coloured powder.
b. Preparation of 1-(6-bromopyrid-2-yl)-1-methyl-3-pentylurea
[0278] 2 g of 6-methylamino-2-bromopyridine are mixed with 3.0 mL
of pentyl isocyanate. The mixture is heated for 12 hours at
100.degree. C. The residue is chromatographed on silica (9/1
heptane/ethyl acetate). 1.8 g of
1-(6-bromopyrid-2-yl)-1-methyl-3-pentylurea are obtained.
Yield=56%.
c. Preparation of methyl 3-butoxy-4-iodobenzoate
[0279] 21.5 mL (0.189 mol, 1.5 eq) of 1-iodobutane are added to a
solution of 35.03 g (0.126 mol, 1 eq) of methyl
3-hydroxy-3-iodobenzoate in 350 ml of methyl ethyl ketone in the
presence of 52.24 g (0.378 mol, 3 eq) of potassium carbonate. The
reaction medium is heated at 85.degree. C. for 2 hours. The solid
is filtered off and the solvent is evaporated off. The solid
obtained is washed with heptane to give 41.78 g of methyl
3-butoxy-4-iodobenzoate in the form of white crystals.
Yield=99%.
d. Preparation of 3-butoxy-4-iodophenyl)methanol
[0280] 8.17 g (0.375 mol, 3 eq) of lithium borohydride are added to
a solution of 41.78 g (0.125 mol, 1 eq) of methyl
3-butoxy-4-iodobenzoate in 210 ml of tetrahydrofuran. The reaction
medium is heated at 60.degree. C. for 2 hours and then hydrolyzed
cautiously with ice-cold saturated ammonium chloride solution. The
reaction medium is neutralized with concentrated hydrochloric acid
and then extracted with ethyl acetate. The organic phases are
washed with water and dried over magnesium sulfate. The solvent is
evaporated off to give 38.31 g of (3-butoxy-4-iodophenyl)methanol
in the form of a whitish oil. Yield=100%.
e. Preparation of 3-butoxy-4-iodobenzaldehyde
[0281] 89.5 g (0.875 mol, 7 eq) of manganese dioxide are added to a
solution of 38.30 g (0.125 mol, 1 eq) of
(3-butoxy-4-iodophenyl)methanol in 250 mL of dichloromethane. The
reaction medium is stirred at room temperature for 18 hours and
then filtered through silica gel. The solvent is evaporated off to
give 29.61 g of 3-butoxy-4-iodobenzaldehyde in the form of an
orange-colored oil. Yield=78%.
f. Preparation of methyl (E)-3-(3-butoxy-4-iodophenyl)acrylate
[0282] 65.08 g (0.195 mol, 2 eq) of methyl
(triphenylphosphoranylidene)acetate are added to a solution of
29.60 g (0.097 mol, 1 eq) of 3-butoxy-4-iodobenzaldehyde in 360 ml
of toluene. The reaction mixture is refluxed for 2 hours. The
solvent is evaporated off and the oil obtained is chromatographed
on silica gel (50/50 heptane/dichloromethane). 30.47 g of methyl
(E)-3-(3-butoxy-4-iodophenyl)acrylate are obtained in the form of
pale yellow crystals. Yield=87%.
g. Preparation of
methyl(E)-3-[3-Butoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phen-
yl]acrylates
[0283] 2.0 g of methyl(E)-3-(3-butoxy-4-iodophenyl)acrylate are
dissolved in 10 mL of dimethylformamide, and 1.8 g of
pinacoldiborane are added, along with 226 mg of
diphenylphosphinoferrocenepalladium dichloride and 1.6 g of
potassium acetate. The mixture is stirred for 3 hours at 90.degree.
C. The reaction is hydrolyzed and extracted with ethyl acetate.
After evaporation of the solvents and chromatography on silica gel
(eluent=7/3 heptane/ethyl acetate), 1.10 g of
methyl(E)-3-[3-butoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phen-
yl]acrylate are obtained. Yield=55%.
h. Preparation of methyl
(E)-3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}acrylate
[0284] 496 mg of
methyl(E)-3-[3-butoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phen-
yl]acrylate are dissolved in 5 mL of dimethylformamide and 1 mL of
2N potassium phosphate solution. 350 mg of
1-(6-bromopyrid-2-yl)-1-methyl-3-phenylurea are added, along with 5
mg of palladium acetate and 16 mg of dicyclohexylbiphenylphosphine.
The mixture is stirred for 3 hours at 90.degree. C. and is then
hydrolyzed and extracted with ethyl acetate. After evaporation of
the solvents and chromatography on silica gel (eluent=7/3
heptane/ethyl acetate), 430 mg of methyl
(E)-3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl-
}acrylate are obtained. Yield=82%.
i. Preparation of methyl
3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}propionate
[0285] A solution of 430 mg of
methyl(E)-3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}acr-
ylate in 5 mL of methanol is stirred for 3 hours at room
temperature in the presence of 100 mg of palladium-on-charcoal,
under a hydrogen atmosphere. After filtering off the palladium and
evaporating off the solvents, 370 mg of methyl
3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}propionate
are obtained. Yield=86%.
j. Synthesis of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-pentylureido)pyridini-
um hydrochloride
[0286] 300 mg of sodium hydroxide are added to a solution of 370 mg
of methyl
3-{3-butoxy-4-[6-(1-methyl-3-pentylureido)pyrid-2-yl]phenyl}propio-
nate dissolved in 15 ml of an 8/2 tetrahydrofuran/methanol mixture.
After stirring for 4 hours at room temperature, the reaction is
stopped with water and acetic acid and is then extracted with ethyl
acetate. The solvents are evaporated off. The residual oil is
chromatographed on silica gel (7/3 heptane/ethyl acetate). 5 mL of
a solution of hydrogen chloride in ethyl acetate are added and the
hydrochloride is precipitated by addition of isopropyl ether. After
filtration, 205 mg of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-pentylureido)pyridini-
um hydrochloride are obtained. Yield=53%.
[0287] .sup.1H NMR (DMSO, 400 MHz): 0.80 (m, 3H); 0.93 (m, 3H);
1.24 (m, 4H); 1.44 (m, 4H); 1.74 (m, 2H); 2.64 (m, 2H); 2.92 (m,
2H); 3.39 (s, 3H); 4.10 (m, 2H); 6.98 (d, J=8 Hz, 1H); 7.13 (s,
1H); 7.24 (d, J=8 Hz, 1H); 7.56 (m, 2H); 7.97 (m, 1H); 9.70 (s,
1H).
Example 12
Synthesis of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-heptylureido)pyridini-
um hydrochloride
##STR00016##
[0288] a. Preparation of
(6-bromopyrid-2-yl)-1-methyl-3-heptylurea
[0289] 2 g of 6-methylamino-2-brompyridine (prepared according to
the procedure of Example 11, step a) are mixed with 3.0 mL of
heptyl isocyanate. The mixture is heated for 12 hours at
100.degree. C. The residue is chromatographed on silica gel (9/1
heptane/ethyl acetate). 2.45 g of
1-(6-bromopyrid-2-yl)-1-methyl-3-heptylurea are obtained.
Yield=71%.
b. Synthesis of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-heptylureido)pyridini-
um hydrochloride
[0290] 300 mg of sodium hydroxide are added to a solution of 377 mg
of methyl
3-{3-butoxy-4-[6-(1-methyl-3-heptylureido)pyrid-2-yl]phenyl}propio-
nate (prepared according to the procedure of Example 11, steps c to
i, replacing the 1-(6-bromopyrid-2-yl)-1-methyl-3-pentylurea with
1-(6-bromopyrid-2-yl)-1-methyl-3-heptylurea in step h) dissolved in
15 mL of an 8/2 tetrahydrofuran/methanol mixture. After stirring
for 4 hours at room temperature, the reaction is stopped with water
and acetic acid and is then extracted with ethyl acetate. The
solvents are evaporated off. The residual oil is chromatographed on
silica gel (7/3 heptane/ethyl acetate). 5 mL of a solution of
hydrogen chloride in ethyl acetate are added, and the hydrochloride
is precipitated by addition of isopropyl ether. After filtration,
220 mg of
2-[2-butoxy-4-(2-carboxyethyl)phenyl]-6-(1-methyl-3-heptylureido)pyridini-
um hydrochloride are obtained. Yield=55%.
[0291] .sup.1H NMR (DMSO, 400 MHz): 0.80 (m, 3H); 0.88 (m, 3H);
1.16 (m, 8H); 1.37 (m, 4H); 1.67 (m, 2H); 2.50 (m, 2H); 2.85 (m,
2H); 3.16 (m, 2H); 3.33 (s, 3H); 4.04 (m, 2H); 6.92 (d, J=8 Hz,
1H); 7.07 (s, 1H); 7.17 (d, J=8 Hz, 1H); 7.50 (m, 2H); 7.91 (m,
1H); 9.70 (s, 1H).
Example 13
Synthesis of
2-[4-(2-carboxyethyl)-2-ethoxyphenyl]-6-(3-heptyl-1-methylureido)pyridini-
um hydrochloride
##STR00017##
[0292] a. Preparation of
3-ethoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzaldehyde
[0293] 2.0 g of ethylvanillin are dissolved in 10 mL of
dichloromethane and 3 mL of triethylamine are then added. 2.36 mL
of triflic anhydride are added slowly at 0.degree. C. After
stirring for 1 hour at 0.degree. C., the reaction is hydrolyzed
with sodium hydrogen carbonate solution and then extracted with
ethyl acetate. After evaporating off the solvents, the oil obtained
is dissolved in 20 ml of dimethylformamide, and 3.96 g of
pinacoldiborane are added, along with 489 mg of
diphenylphosphinoferrocenepalladium dichloride and 3.53 g of
potassium acetate. The mixture is stirred for 3 hours at 90.degree.
C. The reaction is hydrolyzed and then extracted with ethyl
acetate. The solvents are evaporated off and the residue obtained
is chromatographed on silica gel (eluent=7/3 heptane/ethyl
acetate). 1.62 g of
3-ethoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzaldehyde
are obtained. Yield=49%.
b. Preparation of tert-butyl
6-(2-ethoxy-4-formylphenyl)pyrid-2-yl]methylcarbamate
[0294] 1.62 g of
3-ethoxy-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzaldehyde
are dissolved in 15 mL of dimethylformamide, and 3 mL of 2M
potassium phosphate solution and 2.52 g of tert-butyl
(6-bromopyrid-2-yl)methylcarbamate are added, along with 64 mg of
palladium acetate and 200 mg of dicyclohexylbiphenylphosphine. The
mixture is stirred for 3 hours at 90.degree. C. The reaction is
hydrolyzed and then extracted with ethyl acetate. The solvents are
evaporated off and the residue obtained is chromatographed on
silica gel (eluent=7/3 heptane/ethyl acetate). 1.1 g of tert-butyl
6-(2-ethoxy-4-formylphenyl)pyrid-2-yl]methylcarbamate are obtained.
Yield=53%.
c. Preparation of methyl
(E)-3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyphenyl}ac-
rylate
[0295] g of tert-butyl
6-(2-ethoxy-4-formylphenyl)pyrid-2-yl]methylcarbamate are dissolved
in 10 ml of toluene and 1.55 g of methyl
triphenylphosphoranylideneacetate are then added. The reaction
mixture is stirred for 1 hour at 90.degree. C. After evaporating
off the solvent, the residual oil obtained is chromatographed on
silica gel (8/2 heptane/ethyl acetate). 1.0 g of methyl
(E)-3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyph-
enyl}acrylate is obtained. Yield=78%.
d. Preparation of methyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyphenyl}propio-
nate
[0296] A solution of 1.0 g of
methyl(E)-3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyphe-
nyl}acrylate in 10 mL of methanol is stirred for 3 hours at room
temperature in the presence of 200 mg of 10% palladium-on-charcoal
under a hydrogen atmosphere. After filtering off the palladium and
evaporating off the solvents, 1.0 g of methyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyphenyl}propio-
nate is obtained. Yield=100%.
e. Preparation of methyl
3-[3-ethoxy-4-(6-methylaminopyrid-2-yl)phenyl]propionate
[0297] g of methyl
3-{4-[6-(tert-butoxycarbonylmethylamino)pyrid-2-yl]-3-ethoxyphenyl}propio-
nate is dissolved in 10 mL of dichloromethane and 4 mL of
trifluoroacetic acid are then added. The mixture is stirred for 48
hours at room temperature. After hydrolysis of the reaction with
sodium hydrogen carbonate solution and then extraction with ethyl
acetate, the solvents are evaporated off. 615 mg of methyl
3-[3-ethoxy-4-(6-methylaminopyrid-2-yl)phenyl]propionate are
obtained. Yield=81%.
f. Preparation of methyl
3-{3-Ethoxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propionate
[0298] 615 mg of methyl
3-[3-ethoxy-4-(6-methylaminopyrid-2-yl)phenyl]propionate are mixed
with 1.0 mL of heptyl isocyanate. After microwave irradiation for
one hour (T=100.degree. C.), the mixture is chromatographed on
silica gel (9/1 heptane/ethyl acetate). 735 mg of methyl
3-{3-ethoxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propionate
are obtained. Yield=82%.
g. Synthesis of
2-[4-(2-carboxyethyl)-2-ethoxyphenyl]-6-(3-heptyl-1-methylureido)pyridini-
um hydrochloride
[0299] 500 mg of sodium hydroxide are added to a solution of 735 mg
of methyl
3-{3-ethoxy-4-[6-(3-heptyl-1-methylureido)pyrid-2-yl]phenyl}propio-
nate dissolved in 15 ml of an 8/2 tetrahydrofuran/methanol mixture.
After stirring for 4 hours at room temperature, the reaction is
stopped with water and acetic acid and then extracted with ethyl
acetate. The solvents are evaporated off. The residual oil is
chromatographed on silica gel (7/3 heptane/ethyl acetate). 5 mL of
a solution of hydrogen chloride in ethyl acetate are added to the
chromatographed product and the hydrochloride is precipitated by
addition of isopropyl ether. After filtration, 441 mg of
2-[4-(2-carboxyethyl)-2-ethoxyphenyl]-6-(3-heptyl-1-methylureido)pyridini-
um hydrochloride are obtained. Yield=57%.
[0300] .sup.1H NMR (DMSO, 400 MHz): 0.85 (m, 3H); 1.18 (m, 8H);
1.37 (m, 3H); 1.48 (m, 2H); 2.64 (m, 2H); 2.92 (m, 2H); 3.25 (s,
3H); 4.20 (m, 2H); 6.98 (d, J=8 Hz, 1H); 7.12 (s, 1H); 7.25 (d, J=8
Hz, 1H); 7.58 (d, J=8 Hz, 2H); 7.99 (m, 1H); 9.70 (s, 1H).
Example 14
Synthesis of
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propan-
oic acid
##STR00018##
[0301] a. Preparation of
(4-bromothiophen-2-ylmethyl)methylamine
[0302] 10.6 g of 4-bromothiophene-2-carbaldehyde are dissolved in
100 mL of acetonitrile, and 11.8 g of methylamine hydrochloride and
6.28 g of sodium cyanoborohydride are added. The reaction mixture
is stirred overnight at room temperature. The reaction is stopped
with 1M sodium hydroxide solution. After evaporating off the
solvents, the residue is chromatographed on silica gel (7/3
heptane/ethyl acetate). 8.19 g of
(4-bromothiophen-2-ylmethyl)methylamine are obtained.
Yield=79%.
b. Preparation of tert-butyl
(4-bromothiophen-2-ylmethyl)methylcarbamate
[0303] 8.18 g of (4-bromothiophen-2-ylmethyl)methylamine are
dissolved in 80 ml of dichloromethane in the presence of 6.65 ml of
triethylamine. At 0.degree. C., a solution of 9.53 g of
di-tert-butyl dicarbonate in 10 ml of dichloromethane is added
slowly. The reaction mixture is stirred for 2 hours at room
temperature. The reaction is stopped with water and is then
extracted with ethyl acetate. After evaporating off the solvents,
the residue is chromatographed on silica gel (7/3 heptane/ethyl
acetate). 5.93 g of tert-butyl
(4-bromothiophen-2-ylmethyl)methylcarbamate are obtained.
Yield=49%.
c. Preparation of tert-butyl
methyl-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)thiophen-2-ylmethy-
l]carbamate
[0304] 5.92 g of tert-butyl
(4-bromothiophen-2-ylmethyl)methylcarbamate are dissolved in 70 ml
of dimethylformamide, and 5.89 g of pinacoldiborane are added along
with 776 mg of diphenylphosphinoferrocenepalladium dichloride and
5.59 g of potassium acetate. The mixture is stirred for 3 hours at
90.degree. C. The reaction is stopped with water and then extracted
with ethyl acetate. The solvents are evaporated off. The residue is
chromatographed on silica (eluent=7/3 heptane/ethyl acetate). 4.57
g of tert-butyl
methyl-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)thiophen-2-ylmethy-
l]carbamate are obtained. Yield=63%.
d. Preparation of methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)acrylate
[0305] 2.50 g of tert-butyl
methyl-[4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)thiophen-2-ylmethy-
l]carbamate are dissolved in 27 ml of dimethylformamide, and 5.5 mL
of 2M potassium phosphate solution and 1.96 g of methyl
(E)-3-(3-butoxy-4-iodophenyl)acrylate (prepared according to the
procedure of Example 11, step f), are added, along with 12 mg of
palladium acetate and 38 mg of dicyclohexylbiphenylphosphine. The
mixture is stirred for 1 hour at 90.degree. C. The reaction is
stopped with water and then extracted with ethyl acetate. The
solvents are evaporated off. The residue is chromatographed on
silica (eluent=7/3 heptane/ethyl acetate). 1.98 g of methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)acrylate are obtained. Yield=79%.
e. Preparation of methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)propionate
[0306] 1.98 g of methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)acrylate are dissolved in 20 ml of methanol and stirred
for 12 hours at room temperature in the presence of 1.0 g of
palladium-on-charcoal under a hydrogen atmosphere. After filtering
off the palladium and evaporating off the solvents, 1.37 g of
methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)propionate are obtained. Yield=69%.
f. Preparation of methyl
3-[3-butoxy-4-(5-methylaminomethylthiophen-3-yl)phenyl]propionate
[0307] 1.36 g of methyl
(E)-3-(3-butoxy-4-{5-[(tert-butoxycarbonylmethylamino)methyl]thiophen-3-y-
l}phenyl)propionate are dissolved in 15 ml of dichloromethane and
2.2 ml of trifluoroacetic acid are then added. The mixture is
stirred for 2 hours at room temperature. After hydrolyzing the
reaction with sodium hydrogen carbonate solution and then
extracting with ethyl acetate and evaporating off the solvents,
1.15 g of methyl
3-[3-butoxy-4-(5-methylaminomethylthiophen-3-yl)phenyl]propionate
are obtained. Yield=100%.
g. Preparation of methyl
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propio-
nate
[0308] 1.07 g of methyl
3-[3-butoxy-4-(5-methylaminomethylthiophen-3-yl)phenyl]propionate
are dissolved in 20 mL of dichloromethane, and 1.25 mL of
triethylamine are added, along with 36 mg of dimethylaminopyridine.
318 mg of octanoyl chloride are added. The reaction mixture is
stirred for 12 hours at room temperature. After hydrolyzing the
reaction with sodium hydrogen carbonate solution and then
extracting with ethyl acetate and evaporating off the solvents, a
crude product is obtained, which is chromatographed on silica gel
(eluent=7/3 heptane/ethyl acetate). 432 mg of methyl
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propio-
nate are obtained. Yield=81%.
h. Synthesis of
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propan-
oic acid
[0309] 350 mg of sodium hydroxide are added to a solution of 427 mg
of methyl
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl-
)propionate dissolved in 10 mL of methanol. After stirring for 2
hours at 40.degree. C., the reaction is hydrolyzed with
hydrochloric acid solution and then extracted with ethyl acetate.
The solvents are evaporated off. The residual oil is crystallized
from a heptane/ethyl ether mixture.
[0310] 318 mg of
3-(3-butoxy-4-{5-[(methyloctanoylamino)methyl]thiophen-3-yl}phenyl)propan-
oic acid are obtained. Yield=77%.
[0311] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.85 (m, 3H); 1.28 (m,
8H); 1.49 (m, 2H); 1.60 (m, 2H); 1.79 (m, 2H); 2.33&2.48
(2m(rotamers), 2H); 2.65 (m, 2H); 2.95 (m, 2H); 2.99 (s, 3H); 4.00
(m, 2H); 4.65&4.72 (2s(rotamers), 2H); 6.80 (m, 2H); 7.27 (m,
2H); 7.37 (m, 1H); 7.49 (m, 1H).
Example 15
Synthesis of
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid
##STR00019##
[0312] a. Preparation of methyl
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propionate
[0313] 1.07 g of methyl
3-[3-butoxy-4-(5-methylaminomethylthiophen-3-yl)phenyl]propionate
(prepared according to the procedure of Example 14, steps a to f)
are dissolved in 20 ml of dichloromethane, and 1.25 ml of
triethylamine are added, along with 36 mg of dimethylaminopyridine.
270 mg of 4-methoxybenzoyl chloride are added. The reaction mixture
is stirred for 12 hours at room temperature. The reaction is
stopped with sodium hydrogen carbonate solution and then extracted
with ethyl acetate. The solvents are evaporated off. The residue is
chromatographed on silica (eluent=7/3 heptane/ethyl acetate).
[0314] 388 mg of methyl
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propionate are obtained. Yield=71%.
b. Synthesis of
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid
[0315] 308 mg of sodium hydroxide are added to a solution of 382 mg
of methyl
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-
-yl)phenyl]propionate dissolved in 10 mL of methanol. After
stirring for 2 hours at 40.degree. C., the reaction is hydrolyzed
with hydrochloric acid solution and then extracted with ethyl
acetate. The solvents are evaporated off. The residual oil is
crystallized from a heptane/ethyl ether mixture.
[0316] 300 mg of
3-[3-butoxy-4-(5-{[(4-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid are obtained. Yield=81%.
[0317] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.95 (m, 3H); 1.47 (m,
2H); 1.79 (m, 2H); 2.70 (m, 2H); 2.96 (m, 2H); 3.09 (s, 3H); 3.82
(s, 3H); 4.00 (m, 2H); 4.79 (s, 2H); 6.81 (m, 2H); 6.88 (m, 3H);
7.24-7.52 (m, 4H).
Example 16
Synthesis of
3-[3-butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid
##STR00020##
[0318] a. Preparation of methyl
3-[3-butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propionate
[0319] 1.07 g of methyl
3-[3-butoxy-4-(5-methylaminomethylthiophen-3-yl)phenyl]propionate
(prepared according to the procedure of Example 14, steps a to f)
are dissolved in 20 mL of dichloromethane, and 1.25 ml of
triethylamine are added, along with 36 mg of dimethylaminopyridine.
270 mg of 3-methoxybenzoyl chloride are added. The reaction mixture
is stirred for 12 hours at room temperature. The reaction is
stopped with sodium hydrogen carbonate solution and then extracted
with ethyl acetate. The solvents are evaporated off. The residue is
chromatographed on silica (eluent=7/3 heptane/ethyl acetate).
[0320] 380 mg of methyl
3-[3-butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propionate are obtained. Yield=70%.
b. Synthesis of
3-[3-butoxy-4-(5-[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phen-
yl]propanoic acid
[0321] 302 mg of sodium hydroxide are added to a solution of 374 mg
of methyl
3-[3-butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-
-yl)phenyl]propionate dissolved in 10 mL of methanol. After
stirring for 2 hours at 40.degree. C., the reaction is hydrolyzed
with hydrochloric acid solution and then extracted with ethyl
acetate. The solvents are evaporated off. The residual oil is
crystallized from a heptane/ethyl ether mixture.
[0322] 307 mg of
3-[3-butoxy-4-(5-{[(3-methoxybenzoyl)methylamino]methyl}thiophen-3-yl)phe-
nyl]propanoic acid are obtained. Yield=84%.
[0323] .sup.1H NMR (CDCl.sub.3, 400 MHz): 0.95 (m, 3H); 1.47 (m,
2H); 1.79 (m, 2H); 2.69 (m, 2H); 2.96 (m, 2H); 3.10 (s, 3H); 3.81
(s, 3H); 4.00 (m, 2H); 4.62&4.88 (2s(rotamers), 2H); 6.81 (m,
2H); 6.96 (m, 3H); 7.26-7.52 (m, 4H).
Example 17
Crossover-Curve PPAR Transactivation Tests
[0324] The activation of PPAR receptors with an agonist (activator)
in HeLN cells leads to the expression of a reporter gene,
luciferase, which, in the presence of a substrate, generates light.
The modulation of the PPAR receptors is measured by quantifying the
luminescence produced after incubating the cells in the presence of
a reference agonist. The ligands displace the agonist from its
site. The measurement of the activity is performed by quantifying
the light produced. This measurement makes it possible to determine
the modulatory activity of the compounds according to the invention
by determining the constant that is the affinity of the molecule
for the PPAR receptor. Since this value can fluctuate depending on
the basal activity and the expression of the receptor, it is
referred to as Kd apparent (KdApp in nM).
[0325] To determine this constant, "crossover curves" of the test
product against a reference agonist are performed in a 96-well
plate: 10 concentrations of the test product plus a concentration 0
are arranged in a line, and 7 concentrations of the agonist plus a
concentration 0 are arranged in a column. This is 88 measurement
points for 1 product and 1 receptor. The remaining 8 wells are used
for repeatability controls.
[0326] In each well, the cells are in contact with a concentration
of the test product and a concentration of the reference agonist,
2-(4-{2-[3-(2,4-difluorophenyl)-1-heptylureido]ethyl}phenylsulfanyl)-2-me-
thylpropionic acid for PPAR.alpha.,
{2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-ylmethylsulfan-
yl]phenoxy}acetic acid for PPAR.delta. and
5-{4-[2-(methylpyrid-2-ylamino)ethoxy]benzyl}thiazolidine-2,4-dione
for PPAR.gamma.. Measurements are also taken for total agonist
controls with the same products.
[0327] The HeLN cell lines used are stable transfectants containing
the plasmids ERE-.beta.Glob-Luc-SV-Neo (reporter gene) and PPAR
(.alpha., .delta., .gamma.) Gal-hPPAR. These cells are inoculated
into 96-well plates at a rate of 10 000 cells per well in 100 .mu.l
of DMEM medium without phenol red and supplemented with 10% of
defatted calf serum. The plates are then incubated at 37.degree. C.
and 7% CO.sub.2 for 16 hours.
[0328] The various dilutions of the test products and of the
reference ligand are added at a rate of 5 .mu.l per well. The
plates are then incubated for 18 hours at 37.degree. C. and 7%
CO.sub.2. The culture medium is removed by turning over and 100
.mu.l of a 1:1 PBS/luciferine mixture are added to each well. After
5 minutes, the plates are read by the luminescence detector.
[0329] These crossed curves make it possible to determine the AC50
values (concentration at which 50% activation is observed) of the
reference ligand at various concentrations of test product. These
AC50 values are used to calculate the Schild regression by plotting
a straight line corresponding to the Schild equation ("Quantitation
in Receptor Pharmacology" Terry P. Kenakin, Receptors and Channels,
2001, 7, 371-385) which allows the Kd app values (in nM) to be
obtained.
[0330] Transactivation Results:
TABLE-US-00001 PPAR.alpha. PPAR.delta. PPAR.gamma. Kd app Kd app Kd
app Compounds (nM) (in nM) (in nM) Reference 1: 2-(4-{2-[3-(2,4-
200 n.a. n.a. difluorophenyl)-1-
heptylureido]ethyl}phenylsulfanyl)-2- methylpropanoic acid
Reference 2: {2-methyl-4-[4-methyl-2- n.a. 10 n.a.
(4-trifluoromethylphenyl)thiazol-5- ylmethylsulfanyl]phenoxy}acetic
acid Reference 3: 5-{4-[2-(methylpyrid-2- n.a. n.a. 30
ylamino)ethoxy]benzyl}thiazolidine- 2,4-dione Compound of Example 1
n.a. n.a. 1000 Compound of Example 6 n.a. 4000 250 Compound of
Example 2 n.a. n.a. 500 Compound of Example 7 n.a. n.a. 60 Compound
of Example 8 n.a. n.a. 1000 Compound of Example 11 2000 n.a. 120
Compound of Example 12 4000 n.a. 15 Compound of Example 13 4000
8000 120 Compound of Example 14 n.a. n.a. 2 Compound of Example 15
n.a. n.a. 30 Compound of Example 16 n.a. n.a. 30 n.a. means not
active
[0331] These results show the affinity of the compounds for
PPAR.gamma. and more particularly the specificity of the affinity
of the compounds of the invention for the PPAR.gamma. subtype,
compared with the affinity of the compounds for the PPAR.alpha.
subtype or for the PPAR.gamma. subtype.
Example 18
Compositions
[0332] Various specific formulations based on the compounds
according to the invention are illustrated in this example.
[0333] A--Oral Route:
[0334] (a) 0.2 g Tablet:
TABLE-US-00002 Compound of Example 1 0.001 g Starch 0.114 g
Dicalcium phosphate 0.020 g Silica 0.020 g Lactose 0.030 g Talc
0.010 g Magnesium stearate 0.005 g
[0335] (b) Drinkable Suspension in 5 ml Ampules:
TABLE-US-00003 Compound of Example 5 0.001 g Glycerol 0.500 g 70%
Sorbitol 0.500 g Sodium saccharinate 0.010 g Methyl
para-hydroxybenzoate 0.040 g Flavoring qs Purified water qs 5
ml
[0336] (c) 0.8 g Tablet:
TABLE-US-00004 Compound of Example 2 0.500 g Pregelatinized starch
0.100 g Microcrystalline cellulose 0.115 g Lactose 0.075 g
Magnesium stearate 0.010 g
[0337] (d) Drinkable Suspension in 10 ml Ampules:
TABLE-US-00005 Compound of Example 4 0.200 g Glycerol 1.000 g 70%
Sorbitol 1.000 g Sodium saccharinate 0.010 g Methyl
para-hydroxybenzoate 0.080 g Flavoring qs Purified water qs 10
ml
[0338] B--Topical Route:
[0339] (a) Ointment:
TABLE-US-00006 Compound of Example 6 0.020 g Isopropyl myristate
81.700 g Liquid petroleum jelly fluid 9.100 g Silica ("Aerosil 200"
marketed by 9.180 g Degussa)
[0340] (b) Ointment:
TABLE-US-00007 Compound of Example 2 0.150 g Compound of Example 4
0.150 g White petroleum jelly codex qs 100 g.sup.
[0341] (c) Nonionic Water-in-Oil Cream:
TABLE-US-00008 Compound of Example 1 0.100 g Mixture of emulsifying
lanolin alcohols, 39.900 g waxes and oils ("Anhydrous Eucerin"
marketed by BDF) Methyl para-hydroxybenzoate 0.075 g Propyl
para-hydroxybenzoate 0.075 g Sterile demineralized water qs 100
g.sup.
[0342] (d) Lotion:
TABLE-US-00009 Compound of Example 3 0.100 g Polyethylene glycol
(PEG 400) 69.900 g 95% Ethanol 30.000 g
[0343] (e) Hydrophobic Ointment:
TABLE-US-00010 Compound of Example 5 0.300 g Isopropyl myristate
36.400 g Silicone oil ("Rhodorsil 47 V 300" 36.400 g marketed by
Rhone-Poulenc) Beeswax 13.600 g Silicone oil ("Abil 300,000 cst"
marketed qs 100 g by Goldschmidt)
[0344] (f) Nonionic Oil-in-Water Cream:
TABLE-US-00011 Compound of Example 2 1.000 g Cetyl alcohol 4.000 g
Glyceryl monostearate 2.500 g PEG-50 stearate 2.500 g Karite butter
9.200 g Propylene glycol 2.000 g Methyl para-hydroxybenzoate 0.075
g Propyl para-hydroxybenzoate 0.075 g Sterile demineralized water
qs 100 g.sup.
[0345] Each patent, patent application, publication, text and
literature article/report cited or indicated herein is hereby
expressly incorporated by reference.
[0346] While the invention has been described in terms of various
specific and preferred embodiments, the skilled artisan will
appreciate that various modifications, substitutions, omissions,
and changes may be made without departing from the spirit thereof.
Accordingly, it is intended that the scope of the present invention
be limited solely by the scope of the following claims, including
equivalents thereof.
* * * * *